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Diseases affecting the central nervous system (CNS) pose a formidable obstacle to the delivery of
effective therapeutics. A tight-knit collection of cells and macromolecules known as the blood-brainbarrier (BBB) prevents most substances from entering the brain. One intriguing approach to overcoming
this obstacle involves transplanting neural stem cells (NSCs), the precursor cells to neurons and glia in
the brain, as vehicles for the delivery of therapeutic proteins in their native environment. Notably, this
strategy has already been successfully applied to several lysosomal storage diseases caused by genetic
deficiencies in one of the many lysosomal hydrolases expressed throughout the body. A major drawback
to this approach is that foreign NSCs, e.g. immortalized cell lines and primary fetal NSCs can be
tumorigenic and immunogenic. Recently developed induced pluripotent stem cell (iPSC) technologies,
combined with pluripotent stem cell differentiation techniques, have the potential to overcome these
obstacles. This approach was evaluated using a comprehensive strategy targeting a prototypical
lysosomal storage disease, Sly disease (MPS VII). MPS VII patient fibroblasts were transduced with
retroviral vectors expressing the transcription factors Oct4, Sox2, Klf4, and c-Myc. Patient fibroblasts were
reprogrammed into embryonic stem cell-like iPSCs that demonstrated hallmarks of pluripotency. Patient
iPSCs, alongside iPSCs derived from an unaffected individual, were subjected to a stepwise
differentiation protocol, yielding a relatively homogenous population of NSCs. Following in vitro
characterization, patient iPSCs were genetically corrected using a DNA transposon-based vector.
Transplantation of NSCs into neonatal MPS VII mice revealed that these cells could migrate long
distances and survive for several months. However, corrected grafts expressing physiological levels of
the missing enzyme, β-glucuronidase, were too sparse to significantly ameliorate pathology. In contrast,
the same cells transplanted into the post-symptomatic adult MPS VII striatum were restricted to the
injection site. Corrected, but not uncorrected patient iPSC-NSCs, were able to restore pathologically
activated microglia to a normal quiescent state in a zone surrounding the graft. Together, these results
provide evidence that ex vivo NSC gene therapy may be a viable option for many lysosomal storage
diseases using easily attainable, non-neural patient tissue.
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ABSTRACT

EX VIVO GENE THERAPY FOR LYSOSOMAL STORAGE DISEASE USING IPSC-DERIVED
NEURAL STEM CELLS

Tagan Aaron Griffin
John H. Wolfe, V.M.D., Ph.D.

Diseases affecting the central nervous system (CNS) pose a formidable obstacle to the delivery
of effective therapeutics. A tight-knit collection of cells and macromolecules known as the bloodbrain-barrier (BBB) prevents most substances from entering the brain. One intriguing approach
to overcoming this obstacle involves transplanting neural stem cells (NSCs), the precursor cells to
neurons and glia in the brain, as vehicles for the delivery of therapeutic proteins in their native
environment. Notably, this strategy has already been successfully applied to several lysosomal
storage diseases caused by genetic deficiencies in one of the many lysosomal hydrolases
expressed throughout the body. A major drawback to this approach is that foreign NSCs, e.g.
immortalized cell lines and primary fetal NSCs can be tumorigenic and immunogenic. Recently
developed induced pluripotent stem cell (iPSC) technologies, combined with pluripotent stem cell
differentiation techniques, have the potential to overcome these obstacles. This approach was
evaluated using a comprehensive strategy targeting a prototypical lysosomal storage disease, Sly
disease (MPS VII). MPS VII patient fibroblasts were transduced with retroviral vectors expressing
the transcription factors Oct4, Sox2, Klf4, and c-Myc. Patient fibroblasts were reprogrammed into
embryonic stem cell-like iPSCs that demonstrated hallmarks of pluripotency. Patient iPSCs,
alongside iPSCs derived from an unaffected individual, were subjected to a stepwise
differentiation protocol, yielding a relatively homogenous population of NSCs. Following in vitro
characterization, patient iPSCs were genetically corrected using a DNA transposon-based vector.
Transplantation of NSCs into neonatal MPS VII mice revealed that these cells could migrate long
distances and survive for several months. However, corrected grafts expressing physiological
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levels of the missing enzyme, β-glucuronidase, were too sparse to significantly ameliorate
pathology. In contrast, the same cells transplanted into the post-symptomatic adult MPS VII
striatum were restricted to the injection site. Corrected, but not uncorrected patient iPSC-NSCs,
were able to restore pathologically activated microglia to a normal quiescent state in a zone
surrounding the graft. Together, these results provide evidence that ex vivo NSC gene therapy
may be a viable option for many lysosomal storage diseases using easily attainable, non-neural
patient tissue.
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CHAPTER 1
General Introduction
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I. Lysosomal Storage Disease and Mucopolysaccharidosis
Optimal cellular health requires a balance between the metabolism and catabolism of
macromolecules within the cell. In concert with the ubiquitin-proteasome system, the lysosome is
responsible for the breakdown and recycling of macromolecules directly from the cytoplasm and
via fusion with vesicles such as phagosomes, autophagosomes, and endosomes. The discovery
of the lysosome was a seminal event in the history of cell biology, winning Christian de Duve the
Nobel Prize in Medicine or Physiology in 1974. It is now increasingly recognized that the
autophagosome-lysosome system acts as a central point of convergence for many cellular
processes, reacting dynamically to the environment and contributing to overall cellular
homeostasis (Behrends et al. 2010). The lysosome consists of many soluble acid hydrolases
(~50) along with dozens of membrane bound proteins (~25 discovered so far) responsible for
trafficking, nutrient sensing, membrane fusion, cytoplasmic import/export, and generation of an
immense pH gradient (Saftig et al. 2009).
Loss-of-function mutations in lysosomal genes are responsible for many diseases related
to defective catabolism within the cell, the lysosomal storage diseases (LSDs). Individually, these
diseases are rare, but as a group they represent one of the most common causes of monogenetic
disease affecting humans today (~1:7500 live births) (Meikle et al. 2004). The majority of LSDs
are the result of genetic mutations that negatively impact the enzymatic function of a soluble
lysosomal hydrolase. Depending on which hydrolase is affected, the consequent accumulation of
the primary substrate/s involved can result in myriad indirect pathologies which are incompletely
understood (Walkley et al. 1998, Settembre et al. 2008, Ohmi et al. 2009).
While many of the pathological cascades accompanying lysosomal dysfunction remain a
mystery, there remains tremendous hope for treating soluble hydrolase deficiencies based on
some of their unique physiological properties. Lysosomal hydrolases are translated in the
endoplasmic reticulum and processed in the golgi to include a terminal mannose-6-phosphate
(M6P) moiety on specific asparagine residues (Brown et al. 1984). M6P receptors concentrated
in the cis-golgi direct bound enzymes through pre-lysosomal compartments towards the lysosome
proper (Griffiths et al. 1988). A minor fraction of M6P-tagged enzymes do not traffic to the
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lysosome but rather escape the cell via endosomal fusion with the cell membrane. Now in the
extracellular space, soluble enzymes can bind M6P receptors on the surface of neighboring cells,
triggering endocytosis and trafficking towards the lysosome (Coutinho et al. 2012). The sensitive
pH dependence of lysosomal hydrolases (~4.5) prevents premature activation prior to reaching
the lysosome. (Roederer et al. 1987). Importantly, this pathway can be exploited to treat the
majority of lysosomal storage diseases.
Definitive evidence for the inter-cellular trafficking of lysosomal hydrolases came from a
series of landmark studies, led by Elizabeth Neufeld’s lab, using mixed fibroblast cultures derived
from two patients with different lysosomal sorage diseases. The cells from both patients
contained pathologically high levels of mucopolysaccharides (known today as
glycosaminoglycans, or GAGs) (Fratantoni et al. 1968). One patient had Hurler’s syndrome
(MPS I), while the other had Hunter’s syndrome (MPS II). The two diseases are clinically related
and both phenotypes exhibit elevated levels of the GAGs heparan sulfate and dermatan sulfate
throughout the body (Wraith 1995). Remarkably, co-culturing MPS I and MPS II fibroblasts
reduced the GAG burden in cells from both patients, a process now referred to as crosscorrection. Neufeld’s group went on to demonstrate that the corrective factors were functional
soluble hydrolases (α-L-iduronidase and iduronidate-2-sulfatase, respectively) absent in diseased
cells (Fratantoni et al. 1968, Fratantoni et al. 1969).
The mucopolysaccharidoses (MPSs) are an important group of LSDs caused by
mutations affecting one of 11 enzymes responsible for the step-wise degradation of GAGs (Platt
et al. 2004). All but one of these diseases are autosomal recessive (MPS II is X-linked) (Berg et
al. 1968). GAGs are a heterogenous group of linear polysaccharides broadly categorized into
groups defined by one of the following component disaccharide units: heparin/heparan sulfate,
chondroitin/dermatan sulfate, keratan sulfate, or hyaluronan. Depending on which enzyme is
defective, patients can accumulate one or more classes of GAG (Esko et al. 2009).
Since the early days of Neufeld’s pioneering studies, the MPSs have been studied
extensively, yielding diverse insights into lysosome biogenesis, autophagy, intracellular
trafficking, neuron dendritogenesis, and gene expression networks (Goodman et al. 1996,
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McGlynn et al. 2004, Settembre et al. 2008, Cox et al. 2012). MPS diseases are utilized not only
for their contributions to basic cell biology, but also to evaluate novel treatment strategies, in part
because of a well-understood therapeutic mechanism (the M6P pathway) and numerous animal
models that recapitulate human LSDs.
Enzyme replacement therapy (ERT) was first developed for Type I Gaucher disease, the
most common LSD (Barton et al. 1990). Unique among enzyme therapeutics, currently approved
formulations of β-glucocerebrosidase for Gaucher disease are modified such that enzyme
glycans terminate in mannose residues. The rationale for this approach was to increase uptake
in macrophages, preferentialy affected in Type I Gaucher disease, via the mannose receptor
rather than the M6P receptor (Brady 2006). Although the benefit of this particular approach is
unproven, ERT is nevertheless effective in treating nonneuronopathic forms of Gaucher disease.
ERT is now available for several LSDs including MPS I, MPSII, and MPS IVA. However, there
remains a fundamental obstacle to treating LSD pathology in the CNS: the blood-brain-barrier.
Gaucher disease patients with the acute neuronopathic form of the disease (L444P) showed no
improvement when treated with recombinant enzyme even very early in life (Prows et al. 1997).
Most LSDs, including the MPSs, have some level of CNS involvement (Platt et al. 2004).
While it has been reported that extremely high levels of IV recombinant enzyme
(20/mg/kg/week) can have modest success in clearing storage lesions in the brains of MPS VII
mice, it is clear that additional strategies are needed (Vogler et al. 2005). Some groups have
reported enzyme activity in the brain following bone marrow transplantation, presumably
mediated by bone marrow derived cells entering the brain (Zheng et al. 2003, Zheng et al. 2004).
However, success requires lethal irradiation or intense chemotherapy, creating a niche into which
bone marrow derived monocytes can enter the brain to replace resident microglia (Morganti et al.
2014). It has since been demonstrated that the yolk-sac, and not the bone marrow, is the normal
developmental origin of microglia and other tissue resident macrophages (Perdiguero et al.
2014). Microglia are normally self-renewing, they are replaced by bone marrow derived
precursors at a very low rate under normal circumstances and when the brain is shielded during
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whole-body irradiation (Derecki et al. 2012). These studies demonstrate an unmet need for
effective strategies targeting LSD pathogy in the CNS.

II. Neuropathology of Mucopolysaccharidosis
In order to develop effective CNS therapies, well characterized animal models are crucial.
Naturally occurring and genetically modified animals with MPS have served as some of the best
models for developing therapies targeting the CNS. True homologues of human disease, MPS
animal models have been extensively characterized (Levy et al. 1996, Haskins et al. 2002).
Large animal models of MPS are particularly important for evaluating CNS-targeted therapies.
When compared to mice, animals such as cats and dogs have very large brains, more accurately
representing the challenge of achieving widespread enzyme delivery in humans (Wolfe et al.
2000). Local treatments that work well in mice, such as the injection of viral vectors encoding
lysosomal enzymes, are generally ineffective when it comes to treating global CNS pathology in
large animals and LSD patients (Heuer et al. 2002, Cearley et al. 2007, Ponder et al. 2007,
Worgall et al. 2008).
In order to effectively evaluate corrective therapies, it is important to understand the
complicated pathological sequelae of primary substrate accumulation. As long lived non-dividing
cells, neurons are particularly susceptible to the buildup of GAGs. Consequently, MPS diseases
often involve neurological impairment. Patterns of neuropathology, common to a wide range of
LSDs, provide insights into disease mechanisms and may help guide treatment strategies.
While the primary feature of all MPSs is the intracellular accumulation of undegraded
GAGs, there is a secondary accumulation of products for which GAG degrading enzymes are not
required (Walkley 2004). Primary GAG storage affects the expression and distribution of many
lysosomal enzymes in MPS patients (Kint et al. 1973, Hollak et al. 1994). The GAGs heparan
sulfate and chondroitin sulfate can bind many lysosomal enzymes, decreasing their activity in
vitro (Avila et al. 1975). Interestingly, secondary storage products often do not co-localize with
GAGs, implicating broader defects in endosomal sorting pathways (McGlynn et al. 2004).
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The exact composition of secondary storage products depends on the particular disease.
The brains of mice with MPS I, IIIA, IIIB, and VII were all found to accumulate the gangliosides
GM2 and GM3 in varying amounts. Cholesterol storage was shown in MPS I, IIIA, IIIB, but not in
MPS VII (McGlynn et al. 2004). Specific morphological alterations can be observed in cells
accumulating certain primary or secondary storage products. Alterations include the enlargement
of axon hillocks (meganeurites) and the formation of ectopic dendrites, observed in cortical
pyramidal neurons subsequent to GM2 accumulation (Walkley 2004). Meganeurites are found in
many LSDs including Tay-Sachs, α-mannosidosis, fucosidosis, Batten disease, Niemann-Pick
type C, MPS I, and MPS VI.
GM2 ganglioside is thought to be particularly important in the neuropathology of many
LSDs. Ectopic dendrites, often protruding from the meganeurite, are found exclusively in neurons
accumulating GM2 ganglioside (Goodman et al. 1991). High levels of GM2 ganglioside are not
commonly seen in healthy mature neurons, but they are present in developing neurons
undergoing normal dendritogenesis. One theory is that GM2 may be inappropriately activating
dendritogenesis in susceptible neuronal subtypes, thus contributing to neurological dysfunction
(Goodman et al. 1996).
Another common feature of LSD neurons is the presence of axonal spheroids. These
large swellings, distal to the cell body, are common to a wide range of neurodegenerative
diseases. They contain a dense collection of autophagosomal-like and multivesicular-type bodies
(Platt et al. 2004). Axonal spheroids are most common in GABAergic neurons, especially
purkinje cells in the cerebellum, which are particularly vulnerable to cell death in several LSDs
(March et al. 1997). A characteristic of MPS neurons are “zebra bodies”, so-called for their
multilamellar striped appearance (Bhaumik et al. 1999).
Inflammation is a significant component of many LSDs, including MPS diseases.
Gene expression profiling of the MPS VII mouse brain revealed that many inflammatory-related
transcripts are significantly altered relative to unaffected littermate controls (Parente et al. 2012).
There is evidence that GAGs may directly contribute to this pro-inflammatory state. Heparan
sulfate oligosaccharides can activate microglia in vitro via TLR4, and the extent of microglial
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activation correlates with disease progression in MPS mice (Ohmi et al. 2003, Ausseil et al.
2008). However, deletion of TLR4 or the adapter protein MyD88 did not decrease other markers
of disease progression in MPS IIIB mice, indicating that microglial activation is not a major
determinant of neurodegeneration in this disease (Ausseil et al. 2008). Recently, an MPS
-/-

-/-

-/-

VII/TLR4/complement component 3 (C3) (MPS VII /TLR4 /C3 ) mouse was reported, but the
CNS phenotype was not described (Xing et al. 2015). Neurological function and lifespan in mice
with the LSD Sandhoff disease (GM2 gangliosidosis) are improved when crossed to mice lacking
Macrophage-inflammatory protein 1 alpha (MIP-1α) (Wu et al. 2004). GAGs can bind and
enhance the acitivity of several pro-inflammatory cytokines, including MIP-1α (Ali et al. 2000).
MPS IIIB mice have high levels of perforin and granzyme B transcripts in the brain, suggesting
inappropriate NK or CD8 T cell activity (Villani et al. 2009).
Autophagy is a process involving the selective and non-selective degradation of cytosolic
proteins and entire organelles. Autophagy becomes grossly dysregulated in many LSDs because
lysosomal hydrolases are ultimately responsible for much of the actual degradation following
autophagosome-lysosome fusion (Settembre et al. 2008). Mutant mice lacking key autophagic
proteins gradually accumulate undegraded proteins within large poly-ubiquitinated inclusions,
leading to cell death and severe neurodegeneration (Komatsu et al. 2006). Interestingly, polyubiquitinated inclusions and other hallmarks of defective autophagy are common to many
neurodegenerative diseases including dementia, Parkinson’s, Huntington’s, and Alzheimer’s
(Damme et al. 2014). All the evidence is consistent with a central role for autophagy in the
neurodegenerative process, suggesting that insights gleaned from genetically tractable LSDs
may also apply to more common, idiopathic forms of neurodegenerative disease.
Autophagy and lysosomal biogenesis are tightly regulated at the transcriptional level by
the transcription factor TFEB (Sardiello et al. 2009). mTORC1-dependent phosphorylation of
TFEB results in cytoplasmic sequestration, whereas dephosphorylated TFEB translocates to the
nucleus, greatly enhancing lysosome biogenesis (Roczniak-Ferguson et al. 2012, Settembre et
al. 2012). The coordinated action of TFEB, a master regulator of lysosomal gene expression,
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may explain why some pathological features (e.g., secondary enzyme elevation) are common to
many or all LSDs.
Much of the data regarding neuropathology in the MPS VII mouse brain comes from
electron microscopy and immunohistochemical studies (Levy et al. 1996, Heuer et al. 2002).
Electron micrographs show that lysosomal storage is established by three weeks of age and
gradually increases thereafter. Storage is distributed uniformly in most non-neuronal cells, and
varies among neurons depending on subtype and location. Neurons in the CA2, CA3, and CA4
regions of the hippocampus are heavily distended by cytoplasmic vesicles whereas neurons in
CA1 appear relatively unaffected. Brain regions with a high storage burden correspond to regions
of weak β-glucuronidase activity in normal mice (Levy et al. 1996). Immunohistochemical
staining showed a significant difference in the number of ubiquitin-positive inclusions in MPS VII
and normal mice at 3 months of age (Heuer et al. 2002). By 5 months, additional markers of
neuropathology are present including neurofilament inclusions, Fluoro-Jade positive cells, and
astrogliosis. Following administration of an adeno-associated viral (AAV) vector expressing βglucuronidase, markers of neuropathology were restored to normal levels in the transduced
region (Heuer et al. 2002). Currently, viral vectors are limited in their ability to transduce cells
throughout the brain. This limitation might be overcome, perhaps in the near future, through a
strategic choice of vector serotypes and optimized routes of administration (Cearley et al. 2008,
Hinderer et al. 2014).
Another promising approach to achieving widespread enzyme delivery throughout the
brain is neural stem cell (NSC) transplantation. Over 20 years ago, a mouse NSC line was
shown to migrate widely and secrete therapeutic levels of β-glucuronidase in MPS VII mice
(Snyder et al. 1995). Since that time, key discoveries have made it possible to derive NSCs from
easily accessible patient tissue, but ex vivo gene therapy using this approach has yet to be
demonstrated.
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III. Induced Pluripotent Stem Cells
Experiments by Briggs and King in the 1950s demonstrated that nuclei from frog
blastocysts could be transferred to enucleated oocytes, giving rise to a healthy adult frogs (Briggs
et al. 1952). John Gurdon later showed that nuclei from fully differentiated skin cells could
accomplish the same feat (Gurdon et al. 1975). The clear implication of these studies was that
nuclei removed from fully differentiated cells retained the epigenetic plasticity necessary to derive
the entire embryo. Dolly the sheep famously demonstrated that this phenomenon was not just a
quirk of frog biology (Wilmut 2003). Other milestones of reprogramming include the development
of mouse and human embryonic stem cells (ESCs), derived from the inner cell mass of mice
(Evans et al. 1981, Martin 1981) and men (Thomson et al. 1998).
Less than a decade ago, Shinya Yamanaka demonstrated that retroviral expression of 4
genes (the transcription factors Oct4, Sox2, Klf4, and c-Myc) was sufficient to reprogram somatic
cells to a pluripotent state (Takahashi et al. 2006). When these induced pluripotent stem cells
(iPSCs) were transplanted into a mouse blastocyst they were capable of forming chimeras and
contributing to every cell type in an adult mouse, including germ cells (Wernig et al. 2007).
Shortly thereafter, this same strategy was successfully applied to human cells using the same set
of factors (Takahashi et al. 2007) or a different set (Oct4, Sox2, Nanog, and Lin28) (Yu et al.
2007). With these developments, the field of transcription factor-based nuclear reprogramming
was born.
iPSCs can be generated using relatively simple procedures, leading to the rapid adoption
of this technology as a means to study embryogenesis, create in vitro models of disease, and
develop novel stem cell therapeutics. For extensive reviews on the rapid advances following
Yamanaka’s original discovery, see (Robinton et al. 2012) and (Stadtfeld et al. 2010). There has
been debate over exactly how faithful these iPSCs are to blastocyst-derived ESCs, with some
groups showing that the cell-of-origin biases iPSC gene expression, leaving behind an
“epigenetic memory” (Mikkelsen et al. 2008, Kim et al. 2010, Sullivan et al. 2010). However, most
of these studies used early passage iPSCs, and a preponderance of evidence has shown that
iPSCs gradually lose this epigenetic memory over time. With sufficient passaging under the right
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conditions and cultured in the same lab, iPSCs fall well within the normal variation of ESC lines in
terms of DNA methylation status, histone modifications, and differentiation capacity (Bammler et
al. 2005, Guenther et al. 2010), While some debate remains (Chin et al. 2010), iPSCs and ESCs
can, for most practical purposes, be considered epigenetically and functionally equivalent (Smith
et al. 2009, Zhao et al. 2009, Guenther et al. 2010).
Most labs currently working with iPSCs have been interested in one of three primary
areas of research: basic mechanisms of reprogramming and the epigenetic basis of cell fate,
disease modeling using patient-derived iPSCs, and cell therapy using patient-derived iPSCs
(Kanawaty et al. 2009, Okano et al. 2014, Theunissen et al. 2014). The first labs to isolate iPSCs
were focused on the mechanisms of how the pluripotent state arises and is maintained. iPSCs
are valuable tools for addressing these questions and much has been learned regarding the
molecular mechanisms of reprogramming. How exactly can so few TFs induce a genome-wide
pluripotent state? Can small molecules speed up the process or make it more efficient? How
closely related are pluripotent cells in vitro to their inner cell mass counterparts? Can any
differentiated cell type be converted directly into any other through the proper combination of TF
overexpression? Some of these questions have been answered using iPSC technology, and
many questions remain (Hanna et al. 2010).
Application of high-throughput sequencing techniques yields insights related to global
transcriptional and epigenetic networks and how these change during reprogramming (Kim et al.
2008, Ang et al. 2011). Studies comparing ESCs and blastocysts demonstrated that transcription
factors involved in the reprogramming process, such as Oct4 and Nanog, are the same factors
responsible for maintaining pluripotency in the early blastocyst (Marson et al. 2008). Global
reorganization of gene expression, histone status, and DNA methylation has been found to be a
highly coordinated process. Many factors are involved including polycomb repressor complexes
(Boyer et al. 2006), DNA methyltransferases (Li et al. 2007, Deng et al. 2009), histone
modification complexes (Lessard et al. 2010), microRNAs (Wang et al. 2013) and gene regulatory
networks (Muraro et al. 2013). Using techniques such as ChIPseq, high-throughput DNA and
RNA sequencing, and high-throughput analysis of global DNA methylation and histone status in
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ESCs and iPSCs, we understand much more about the pluripotent state and cell differentiation
than we did only a decade ago (Robinton et al. 2012).
Since the first derivation of human ESCs (Thomson et al. 1998), many labs have focused
on developing protocols to generate specific cell types from pluripotent cells (Odorico et al. 2001).
The advent of iPSC technology allows for the derivation of patient-specific cell types, useful for
disease modeling and cell therapy, which would have been difficult or impossible to obtain
otherwise.

IV. Generating and Utilizing Neural Lineages from Pluripotent Stem Cells
By the early 1990’s, methods were established for the identification of NSCs, as well as
the culture conditions and growth factors required to isolate and maintain primary fetal and adult
NSCs in vitro (Cattaneo et al. 1990, Reynolds et al. 1992, Kilpatrick et al. 1993, Davis et al. 1994,
Palmer et al. 1995). Shortly thereafter, the first therapeutic studies were carried out, using the
MPS VII mouse as a disease model (Snyder et al. 1995). NSCs isolated from the cerebellum of
neonatal mice, immortalized with the oncogene v-Myc (C17.2 cell line) (Ryder et al. 1990, Snyder
et al. 1992), were successfully transplanted into the ventricles of neonatal MPS VII mice (Snyder
et al. 1995). Not only did the cells survive but they migrated widely, delivering sufficient levels of
the missing enzyme, β-glucuronidase (GUSB), to prevent storage lesions throughout the brain
(Snyder et al. 1995). Unfortunately, the use of immortalized cell lines for transplantation has clear
disadvantages, namely the strong likelihood of tumorigenesis or immune rejection in the host.
The MPS VII mouse has served as a useful model for developing new, more clinically relevant
gene and cell therapies in the brain thanks to its well characterized pathology, sensitive and
quantitative enzyme assays, and a viable mechanism for correcting every cell in the brain (crosscorrection) (Wolfe et al. 1990).
Tissue isolated from fetal brains has been proposed as an alternate source of NSCs and
several small trials have evaluated this strategy, with mostly disappointing results (Bjorklund et al.
2000, Aboody et al. 2011, Thomsen et al. 2014). A rare example of success was recently
published following up 2 patients with Parkinson’s disease that had been injected with fetal
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ventral mesencephalic tissue over 15 years ago. Both patients showed moderate motor
improvement over time and were able to discontinue dopaminergic therapy (Kefalopoulou et al.
2014). Many similar trials involving fetal grafts for Parkinson’s disease over the past 30 years
have ended in failure, either because the grafted cells quickly took on the Parkinsonian
phenotype of the surrounding cells (Kordower et al. 2008, Li et al. 2008) or because the grafted
cells actually induced additional dyskinesias (Aboody et al. 2011, Lindvall 2013).
Clearly there is not enough basic knowledge of NSCs, regarding their diversity and their
interactions with diseased environments, to proceed with large-scale clinical trials. More animal
studies are needed to determine the optimal source of transplantable NSCs. If the fetal brain is
not an optimal source, than what is? Pluripotent stem cells have the ability to differentiate into
any cell type in the body, and can now be derived from a patient’s own cells, making them
particularly attractive candidates for NSC therapy.
Many protocols have been developed for the differentiation of pluripotent stem cells
(primarily ESCs) into multipotent neural progenitors as well as mature neurons and glia. While
specific protocols come with advantages and disadvantages, they all rely on similar mechanisms
to recapitulate early neural development (Lanza et al. 2004, Abranches et al. 2009). Nearly every
protocol that successfully induces neural lineage differentiation relies on a stepwise series of
culture conditions, utilizing combinations of signaling molecules at specific dosages and time
points to mimic in utero development. Confirming their functionally similar nature, ESCs and
iPSCs respond the same way to various neuralization protocols (Hu et al. 2010).
Neuralization procedures first recapitulate early neurogenic signaling events involving
molecules such as FGFs, Wnts, and BMPs (Wilson et al. 2001). The first example of directed
neural differentiation from ES cells comes from (Bain et al. 1995). ESCs were detached from
their mouse embryonic fibroblast (MEF) feeder layer to generate spherical aggregates, or
“embryoid bodies” (EBs), which were then exposed to retinoic acid. Many cells within the EBs
differentiated into neuron-like cells characterized by the firing of action potentials and expression
of tetrodotoxin (TTX)-sensitive sodium channels, voltage-gated potassium channels, and calcium
channels (Bain et al. 1995). Exposure to conditioned media from the HepG2 cell line also
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increases the efficiency of EB conversion towards neural lineages (Rathjen et al. 2003). EBs can
be dissociated and grown as a monolayer of neural progenitors, which led to the co-culture of
ESCs with various cells lines in an attempt to convert ESCs even more efficiently. It was found
that certain mouse stromal lines, e.g. PA6 (Kawasaki et al. 2000) or MS5 (Barberi et al. 2003),
support neural differentiation from ESCs quite efficiently.
A crucial refinement to the basic EB protocol by (Okabe et al. 1996) involved plating 4
day-old EBs in fetal calf serum to promote attachment, followed by growth in a minimal neural
induction media. Further passaging of these cells in an optimized NSC media, plus the addition
of cytosine arabinose to inhibit astrogliogenesis, yields relatively pure populations of
transplantable NSCs (Okabe et al. 1996).
One of the easiest and most efficient neural differentiation protocols is known as “dual
SMAD inhibition” (Chambers et al. 2009), which involves the application of only two crucial
morphogens (Noggin, an inhibitor of TGF-β proteins including BMP-4, and the small molecule
SB431542, an inhibitor of several activin receptor-like kinases [AKTs]) (Lamb et al. 1993, Laping
et al. 2002). Following the application of these 2 morphogens, over 80% of ESC or iPSCs
+

become PAX6 early neural progenitor cells that can be further differentiated towards various
mature neuronal subtypes (Chambers et al. 2009).
Another important development in the generation of transplantable NSCs does not
involve pluripotent cells at all. Combinations of transcription factors were shown by several
groups to directly generate neural progenitors, thus bypassing the pluripotent stage (Han et al.
2012, Lujan et al. 2012, Sheng et al. 2012). This method has several advantages, specifically a
lower risk of tumorigenesis following transplantation, as well as the speed at which these cells
can be generated and characterized. It remains to be seen how faithful these cells are to
endogenous and pluripotent cell-derived NSCs, but so far the data seem promising (Lujan et al.
2012).
One particularly interesting feature of neural differentiation is that it seems to be the
default pathway for differentiating pluripotent cells (Munoz-Sanjuan et al. 2002). This indirectly
led to the discovery that BMP-4 is the primary inhibitor of neural induction (Wilson et al. 1995). If
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human ESC cultures, in the absence of exogenous factors, remain in the same culture dish for
several weeks, neural cells begin to emerge (Reubinoff et al. 2001). The addition of FGF and
EGF enhance this induction, allowing NSCs to be cultured as a relatively homogenous population
expressing the neural markers nestin, vimentin, and PAX6 (Reubinoff et al. 2001).
While there are differences in neurodevelopmental signaling pathways between mice and
humans, they appear to be more alike than different (Moon et al. 2006). Similar protocols yield
remarkably similar results and human pluripotent stem cell-derived neural progenitors can
functionally integrate into cortical circuits in mice, although this process can take several months
(Espuny-Camacho et al. 2013). One significant example of a species-specific difference is that
Sox1 is the first neural-associated gene to be expressed in mice while Pax6 (expressed before
Sox1) is both necessary and sufficient for neurectodermal formation in humans (Zhang et al.
2010).
There are several different protocols that give rise to early neural progenitors, but every
method has drawbacks, depending on the application in question. Most protocols generate
neural lineages by recapitulating early neural development. In doing so, they suffer the same fate
as endogenous neural progenitors, demonstrating a shift from a neuronogenic to a gliogenic bias
after many cell divisions, mimicking the situation seen in normal brain development (Abranches et
al. 2009, Edri et al. 2015). Several groups have tried to overcome this bias by selectively
culturing cells at an early “rosette” stage of neural development, reminiscent of the early neural
tube. It has been shown that such cells can retain a broad and consistent differentiation potential
over many passages (Elkabetz et al. 2008, Koch et al. 2009).
Large scale clinical application of ESC/iPSC-derived NSCs will require a level of
consistency that is difficult to obtain using cells that change significantly with passage number. It
would require redifferentiating each batch of cells and extensively testing them for batch-to-batch
variability. So far, a protocol developed by Koch et al. is unique in that it produces cells that
maintain a consistent gene expression profile and differentiation capacity over 100 passages at
an NSC stage (Koch et al. 2009). This method was developed using ESC lines but also works
with iPSCs (Falk et al. 2012). A protocol with similar properties may be ideal for transplantation
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studies or future clinical use. These “long-term self-renewing NSCs” do show a bias towards
generating GABAergic neurons of the hindbrain upon passive withdrawal of growth factors, but
the cells remained responsive to regionalization cues across time, generating both dopaminergic
and motor neurons in appropriate culture conditions (Koch et al. 2009).

V. Rationale
We have devised and evaluated a comprehensive strategy for the treatment of lysosomal
enzyme deficiencies in the brain involving the reprogramming, differentiation, and genetic
correction of diseased somatic cells. We chose MPS VII as a model system because it has been
well characterized and for its long history as a platform for the development of novel therapeutics,
particularly in the brain (Snyder et al. 1995). We used recently developed techniques to
reprogram somatic tissue into pluripotent cells with the rationale that patients would be less likely
to mount a counter-productive immune response against autologous cells. We decided that
NSCs would be most appropriate for cell-based therapy in the brain based on previous studies
demonstrating that NSC cell lines and primary NSCs can respond appropriately to developmental
cues and migrate widely (Flax et al. 1998, Gage et al. 2013). Importantly, immortalized NSCs
have already proven to be effective following transplantation into neonatal and adult MPS VII
mice (Snyder et al. 1995, Buchet et al. 2002).
We hypothesized that a comprehensive strategy, beginning with diseased MPS VII
patient fibroblasts and ending with corrected patient NSCs, would effectively treat an
immunodeficient mouse model of MPS VII. To test this, we derived patient iPSCs from frozen
fibroblasts using a modification of the Park et al. protocol (Park et al. 2008), omitting 2 of the 6
reprogramming factors (hTERT and the SV40 large T antigen) to reduce the risk of tumogenesis.
We then used a protocol previously shown to convert ESC/iPSCs into a stable long-term selfrenewing population of NSCs (Koch et al. 2009). We reasoned that such a population of patientderived iPSC-NSCs would be ideal for expansion, genetic correction, and transplantation. This
combination of cellular reprogramming and genetic engineering techniques is a logical step
towards developing personalized cell-based therapies in the brain.
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CHAPTER 2
Genetically Corrected Neural Stem Cells
Generated from MPS VII Patient Fibroblasts

This chapter is adapted from Griffin TA, Anderson HC, and Wolfe JH. Ex Vivo Gene Therapy
Using Patient iPSC-Derived NSCs Reverses Pathology in the Brain of a Homologous Mouse
Model, Stem Cell Reports (Griffin et al. 2015).
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I. Introduction
Induced pluripotent stem cells are promising candidates for treating many diseases in the
brain. Unfortunately, disease-related mutations can impede this process. It may not be possible
to generate iPSCs from all patients, and differentiation towards therapeutic cell types can be
impeded as well (Hamasaki et al. 2012, Ogawa et al. 2013). It has been reported that iPSCs
from mouse models of some LSDs (Sandhoff and MPS VII) are defective in their ability to
differentiate towards neural lineages, which may severely hamper efforts to generate patient
specific iPSC-derived NSCs suitable for transplantation (Meng et al. 2010, Ogawa et al. 2013).
We hypothesized that β-glucuronidase (GUSB) deficiency should not be an obstacle to the
reprogramming of MPS VII patient cells because of the cross-correction process. Exogenous
GUSB derived from the mouse embryonic feeder (MEF) layer upon which iPSCs are generated
should serve as an adequate source of enzyme for deficient cells (Fratantoni et al. 1968).
However, differentiation requires that iPSCs be removed from the MEF feeder layer, and it was
unclear whether differentiation towards neural lineages would be impaired relative to control
iPSCs.
The current study demonstrates that fibroblasts from a female patient with MPS VII,
frozen for ~30 years, can be reprogrammed through retroviral overexpression of Oct4, Sox2, Klf4,
and c-Myc. The GUSB mutations in these fibroblasts and consequent MPS VII phenotype has
been extensively described elsewhere (Wu et al. 1994). We show that these MPS VII iPSCs
display stringent correlates of pluripotency including teratoma formation. MPS VII iPSCs were
successfully differentiated alongside control iPSCs into long-term self-renewing NSCs using a
protocol developed for ESCs described previously (Koch et al. 2009). Finally, a functional version
of the GUSB gene was introduced into MPS VII iPSC-derived NSCs using a DNA transposonbased vector (PiggyBac), demonstrating a comprehensive strategy that may be useful for
generating clinically relevant transplantable NSCs in the future.

17

II. Results
Generation and characterization of MPS VII iPSCs
Frozen dermal fibroblasts from a patient with MPS VII (GM02784, Coriell Institute) were
thawed, expanded, and transduced with VSV-G pseudotyped retroviral vectors expressing OCT4,
SOX2, KLF-4, and c-MYC to initiate reprogramming. This patient was previously reported to
have 1.4% of normal β-glucuronidase activity in cultured fibroblasts (Wu et al. 1994). Despite the
fact that these fibroblasts had been frozen for ~30 years, colonies of ESC-like cells emerged
alongside aggregates of partially reprogrammed cells, consistent with previous reports (Chan et
al. 2009). One line was selected for further characterization.
To confirm the pluripotency of MPS VII iPSCs, standard in vitro and in vivo assays were
performed. The putative MPS VII iPSC line displayed typical ESC/iPSC-like colony morphology
(Fig. 2.1a) and expressed multiple markers of pluripotency including SSEA4, Tra-1-60, and Tra1-81 (Fig. 2.1b-d). Cells injected into immunodeficient mice formed teratomas containing the
three primary germ layers. Hematoxylin and eosin stained teratoma sections revealed structures
typical of endoderm, ectoderm, and mesoderm (Fig. 1e-h), and immunostained teratoma sections
were positive for markers of each lineage (Fig. 2.1i-k). iPSCs were passaged >40 times with no
change in morphology or pluripotency marker expression.
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Fig. 2.1 Generation of iPSCs from an MPS VII patient. Fibroblasts from a female patient
with MPS VII (GM02784) were transduced with retroviral vectors expressing the reprogramming
factors Oct4, Sox2, Klf4, and c-Myc. A putative iPSC line was isolated and expanded under
serum-free conditions on a feeder layer of mouse embryonic fibroblasts. MPS VII iPSC colonies,
seen in the phase contrast image (a), expressed markers of pluripotency (b-d). After injection
into immunodeficient mice, MPS VII iPSCs formed teratomas (e) that differentiated into the three
primary germ layers as shown by H&E stained sections (e-h) and germ layer specific marker
expression (i-k). α-FP = α-fetoprotein, SMA = smooth muscle actin, Tuj1 = βIII-tubulin, scale bars
= 200µm (except in e).
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Differentiation of MPS VII iPSC-NSCs
MPS VII and control iPSCs were passaged at least 20 times before being subjected to an
adapted NSC differentiation protocol (Koch et al. 2009) (Fig. 2). After iPSCs were removed from
the MEF feeder layer and grown in suspension culture containing FBS, they formed large
spherical aggregates. These “embryoid bodies” were plated and grown in a minimal neural
induction medium. A variety of cell types grew outward from the plated aggregates, including
many with neurite-like extensions. After approximately two weeks, neural tube-like structures
began to form on some cell aggregates, consisting of a raised ring surrounding a central lumen
(Elkabetz et al. 2008). These rosette structures were isolated and grown as neurospheres for two
days, after which they were dissociated and plated, yielding an adherent monolayer. No obvious
differences were observed between normal and MPS VII iPSCs during the differentiation
procedure at any point and both yielded a relatively homogenous population of putative neural
stem cells (Fig. 2.2).

Characterization of MPS VII iPSC-NSCs
The majority of the iPSC-NSCs (89.9 ± 2.9%) retained expression of the neural stem cell
marker nestin (Fig. 3a). The rate of spontaneous differentiation into MAP2-positive neurons (9.5 ±
0.8%) and GFAP-positive astrocytes (0.4 ± 0.6%) was low (Fig. 2.3a,b). Importantly, no cells
expressed the pluripotency marker Tra-1-60 or the reprogramming factor Oct4 (Fig. 2.3a,b). The
generation and culture of iPSCs from frozen MPS VII fibroblasts and the subsequent
differentiation and propagation of iPSC-NSCs did not introduce any gross chromosomal
abnormalities, as shown by a normal 46,XX karyotype (Fig. 2.3c). To test the differentiation
capacity of these cells, they were grown in terminal differentiation medium without growth factors
for one month. Differentiating conditions yielded neurons and astrocytes (Fig. 2.3d), as
measured by MAP2 (86.4 ± 1.6%) and GFAP (13.9 ± 8.2%) expression, respectively (Fig. 2.3e).
The majority of cells (74.8 ± 5.2%) were positive for the inhibitory neurotransmitter GABA, while
there was no evidence of tyrosine hydroxylase-positive dopaminergic neurons (Fig. 2.3d,e).
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Figure 2.2 Differentiation of NSCs from MPS VII and normal iPSCs. Control and MPS VII iPSCs were removed from their MEF
feeder layer and grown in suspension culture with FBS for five days to induce embryoid body formation. The cell clusters were plated onto
poly-ornithine coated dished and grown in neural induction media. Neural tube-like structures (white arrows) began to appear and were
manually isolated at day 20 and cultured in suspension in neurosphere media for two days. Neurospheres were trypsinized and plated
onto poly-ornithine/laminin coated dishes. Trypsinized cells were passaged as nestin-positive NSCs indefinitely.

Figure 2.3 Characterization and terminal differentiation of MPS VII iPSC-NSCs
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Figure 2.3 Characterization and terminal differentiation of MPS VII iPSC-NSCs.
(a,b) MPS VII NSC cultures expressed nestin (89.9 ± 1.5%) and showed low levels of
spontaneous differentiation towards neurons (MAP2, 9.5 ± 0.4%) and astrocytes (GFAP, 0.4% ±
0.3%). No cells expressed the reprogramming factor Oct4 or the pluripotency marker Tra-1-60.
(c) MPS VII iPSC-NSCs had a normal 46,XX karyotype. (d,e) NSCs were subjected to terminal
differentiation by the removal of growth factors and the addition of cAMP for one month. MAP2positive neurons comprised 86.4% ± 0.8% of all differentiated cells. The majority of those cells
(74.8% ± 2.6%) were GABA-positive and none of the cells stained positive for the dopaminergic
marker tyrosine hydroxylase (TH). GFAP-positive astrocytes comprised 13.9% ± 4.1% of all
differentiated cells. Data are represented as the mean ± SEM, n=4 independent cultures. Scale
bars = 200µm

Generation of GFP labeled and GUSB expressing MPS VII iPSCs
To introduce GFP into NSCs for the purpose of tracking their engraftment following
transplantation, we first evaluated previously optimized transduction conditions using VSV-G
pseudotyped lentiviral vector preps that had been extensively validated both in vitro and in vivo.
Surprising, iPSC-derived NSCs proved exquisitely sensitive to lentiviral vectors. Multiple
attempts with different pseudotypes consistently resulted in cell death at MOIs >10 and were
ineffective at transducing cells when the MOI < 10. We therefore decided to switch to a PiggyBac
transposon-based system consisting of 2 plasmids. The first plasmid contains terminal repeats
flanking two promoter units in tandem. The 5’ promoter (CMV) drives expression of GUSB,
followed by the EF1α promoter, which drives expression of both GFP and a puromycin resistance
gene via a 2A polypeptide linker. The second plasmid transiently expresses a transposase
capable of integrating plasmid sequence bounded by terminal repeats into the genome at TTAA
sites. The use of a Lonza nucleofector and proprietary transfection reagents was very efficient at
introducing vectors into iPSC-derived NSCs (fig..2.4a). However, when we placed a gene
downstream of the CMV promoter (or CAG, switched to avoid promoter shutdown in the brain
(Gray et al. 2011)), we observed very high levels of the transgene driven by the upstream
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promoter, but expression of GFP and the puro resistance gene driven by EF1α was barely
detectable.
The iPSC-NSCs were electroporated with a PiggyBac vector containing GUSB cDNA
driven by the CAG promoter. A separate culture of the same passage of NSCs was prepared as
a negative control by electroporating them with a mock-correction vector containing GUSB cDNA
in the reverse orientation (revGUSB). Following puromycin selection, mock-corrected MPS VII
iPSC-NSCs had negligible GUSB activity (1.3 ± 1.3 nmol 4-MU/µg protein/ hr) while the corrected
cells showed strong GUSB activity (116.8 ± 2.7 nmol 4-MU/µg protein/hr, p<0.01), comparable to
an iPSC-NSC line derived from a healthy control (112.3 ± 3.1 nmol 4-MU/µg protein/hr, p >0.05)
(Fig. 2d).
To evaluate the issue of low expression from the downstream promoter, several
transgenes or non-coding sequences were placed under the control of the upstream CAG
promoter (GUSB, revGUSB, sialidase, EGFRVII, reprog), all of which had the same effect on
GFP expression. Expression of the puromycin resistance gene was good enough to select for
transduced cells (fig. 2.4d) thanks in part to the sensitivity of iPSC-NSCs to puromycin, but no
GFP could be visualized, even after immunohistochemistry for GFP protein. We therefore used
three populations of cells for future transplantation experiments: uncorrected/GFP-positive NSCs,
corrected/GFP-negative NSCs, and mock-corrected/GFP-negative cells. Further experiments
using 293t cells demonstrated that replacing CAG with the minimal GUSB promoter results in
much higher levels of GUSB as well as restoring strong expression of GFP and puromycin
resistance from the EF1α promoter (fig. 2.5).
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Figure 2.4 A PigyBac transposon vector efficiently introduces GFP or GUSB into
MPS VII iPSC-derived NSCs. (a) A PiggyBac transposon-based plasmid encoding GFP and
a puromycin resistance gene was electroporated into MPS VII iPSC-NSCs. (b) Puromycin was
applied for 7 days in order to select for NSCs that had been stably transduced. (c) MPS VII
iPSC-NSCs retained their nestin expression and growth capacity after electroporation and
puromycin selection. (d) Levels of β-glucuronidase expression in iPSC-derived NSCs from a
normal control compared to MPS VII iPSC-derived NSCs receiving PiggyBac vector containing
GUSB cDNA in the reverse orientation (mock-corrected) or GUSB in the forward orientation
(corrected).
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Figure 2.5 Effect of Promoter Choice on GUSB and GFP levels
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Figure 2.5 The Effect of Promoter Choice on GUSB and GFP levels. The dual
promoter PiggyBac system (Systems Biosciences) vector suffers from a major flaw. When a
coding sequence (or non-coding sequence [revGUSB]) (b,c) is inserted into the multiple cloning
site downstream of the CMV or CAG promoter, GFP expression from the EF1α promoter is
severely reduced. This is consistent with either promoter-shutdown or frank toxicity, both of
which have been described previously (van den Pol et al. 1998, Papadakis et al. 2004). (e) Map
of the dual expression plasmid vector. (f) Transient transfection of 293t cells with
PB.GUSB.GUSB shows improved GFP expression from the second promoter and much higher
levels of GUSB expression. PB.CAG.MCS = PiggyBac driven by the CAG promoter with nothing
inserted into the multiple cloning site. PB.CAG.GUSB = PiggyBac driven by the CAG promoter
with GUSB cDNA inserted into the multiple cloning site. PB.CMV.Reprog = PiggyBac driven by
the CMV promoter with a quadrivalent set of reprogramming cDNAs inserted into the multiple
cloning site. PB.GUSB.GUSB = PiggyBac driven by the minimal GUSB promoter (~500 bp
upstream of the start site) with GUSB cDNA inserted into the multiple cloning site.
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III. Discussion
First and foremost, these results demonstrate that a deficiency in GUSB does not
preclude the generation of iPSCs or neural stem cells. Given that deficient fibroblasts have
access to exogenous enzyme from the MEF feeder layer during the reprogramming process, we
predicted that GUSB deficiency would not be an obstacle to reprogramming. It would have been
preferable to use fresh patient cells, but the scarcity of MPS VII patient samples precluded this
possibility. Because our patient sample had been frozen so long ago, and given how extensively
it has been utilized, it’s unclear how many divisions these cells have gone through. Both of these
factors (long-term freeze and high passage number) are known to reduce the efficiency of
reprogramming. As somatic cells divide, several factors decrease the efficiency of
reprogramming, notably telomerase length (Huang et al. 2011). We modified the iPSC
generation protocol developed by Park et al. through the omission of the reprogramming factors
telomerase (hTERT) and the SV40 large T antigen (Park et al. 2008). Potential consequences of
including these factors include tumorigenesis and chromosomal instability (Ouellette et al. 2000,
Ali et al. 2001). Many groups have derived iPSCs without these factors, and we decided to omit
them at the price of reprogramming efficiency.
Subsequent to the generation of our MPS VII iPSCs, an article was published reporting
the generation of iPSCs from three mouse models of LSD, including MPS VII (Meng et al. 2010).
Of the LSDs examined, MPS VII iPSCs displayed defects in their differentiation capacity as
measured by a significant decrease in the number and size of embryoid bodies generated when
iPSCs were removed from their MEF feeder layer. Exogenous application of recombinant βglucuronidase partially corrected this defect (Meng et al. 2010). Another paper using a mouse
model of the LSD Sandhoff disease showed specific defects in neural differentiation, raising
further doubts about the ability to generate neural lineages from our human MPS VII iPSCs
(Ogawa et al. 2013).
In seeming contradiction to the Meng et al. study, when our MPS VII iPSCs were
removed from the MEFs alongside control iPSCs, we saw no obvious differences in the ability to
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generate neural lineages or long-term self-renewing NSCs. Many factors could explain this
discrepancy, including subtle differences in differentiation protocols, species-specific differences,
or low levels of GUSB activity in the human iPSCs. While undetectable using fluorometric
methods in our lab, the patient fibroblasts were previously reported to express 1.4% normal levels
of β-glucuronidase (Wu et al. 1994). Human GUSB mutations resulting in the complete absence
of β-glucuronidase activity usually result in pre-term or neonatal mortality (Vervoort et al. 1997,
Vervoort et al. 1997, Tomatsu et al. 2009). In contrast, MPS VII mice can be viable in the
complete absence of detectable β-glucuronidase activity, indicating the possibility of speciesspecific differences (Sands et al. 1993). Whatever the reason, our results clearly show that MPS
VII patient fibroblasts can be reprogrammed. Furthermore, they can be removed from all
potential sources of exogenous enzyme, and differentiated into long-term self-renewing NSCs
capable of generating mature neurons and glia.
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CHAPTER 3
MPS VII iPSC-Derived Neural Stem Cells Engraft Widely in Neonates
and Correct Microglial Pathology in Adult MPS VII Mice

This chapter is adapted from Griffin TA, Anderson HC, and Wolfe JH. Ex Vivo Gene Therapy
Using Patient iPSC-Derived NSCs Reverses Pathology in the Brain of a Homologous Mouse
Model, Stem Cell Reports (Griffin et al. 2015).
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I. Introduction
A combination of iPSC generation from easily accessible patient tissue, NSC
differentiation protocols, ex vivo gene therapy, and transplantation directly back into the patient,
may be an effective strategy for treating many LSDs. In this chapter we transplant MPS VII iPSCderived NSCs into the brains of neonatal and adult mice with MPS VII. To prevent immune
rejection of human cells we used the immunodeficient NOD/SCID/MPS VII model previously
described (Hofling et al. 2003). GFP-labeled MPS VII iPSC-derived NSCs were transplanted in
the ventricles of neonatal NOD/SCID and NOD/SCID/MPS VII littermates to evaluate the patterns
and persistence of engraftment over the course of 4 months. Corrected or mock-corrected MPS
VII NSCs were also injected into the post-symptomatic striatum of 2 month old mice to evaluate
the extent of disease correction. We identified CD68-positive, activated microglia as an easily
quantifiable biomarker of CNS pathology in these animals. This strategy permitted us to visualize
engrafted cells and neuropathology in the same samples. We further validated this method using
an adeno-associated viral vector expressing β-glucuronidase in MPS VII mice.
Following neonatal intraventricular transplantation, iPSC-NSCs engraft throughout the
rostrocaudal axis of the CNS, primarily within white matter tracts, and survive for at least four
months with little evidence of differentiation. Genetically corrected and mock-corrected cells,
while dispersed widely, were unable to correct microglial pathology. Transplanted cells exited the
cell-cycle rapidly and no differences were found between MPS VII and normal iPSC-NSCs
engrafted in normal and MPS VII mice. Genetically corrected MPS VII iPSC-NSCs transplanted
post-symptomatically into the striatum of adult NOD/SCID/MPS VII mice reversed neuropathology
in a zone surrounding the grafts, while control mock-corrected grafts did not. MPS VII and control
iPSC-NSCS did not migrate from the injection site, more consistent with data from primary NSCs
than immortalized NSC lines. The results suggest that improvements are needed to increase
survival, enzyme expression levels, and migration, especially in adult animals. However, the
dramatic amelioration of microglial pathology surrounding the corrected grafts provides a
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compelling argument for ex vivo gene therapy in the brain using human NSCs from autologous,
non-neural tissues.

II. Results
MPS VII patient iPSC-derived NSCs engraft widely in the neonatal brain
To assess the engraftment potential of MPS VII iPSC-NSCs, GFP-labeled cells were
injected intraventricularly into neonatal mice, which provide a more hospitable environment for
engraftment relative to the adult brain (Snyder et al. 1995). Over 100 NOD-SCID neonates were
injected with iPSC-NSCs between passages 15-25 with no evidence of deleterious effects in
behavior or gross brain structure. By 1 month post-transplant, cells had engrafted along the
rostrocaudal axis of the brain and were primarily found in periventricular regions and white matter
tracts (Fig. 3.1). Regardless of location, the engrafted cells expressed nestin and had an
immature morphology (Fig. 3.1, lower panels). GFP-labeled MPS VII iPSC-NSCs were also
transplanted into NOD/SCID/MPS VII neonates. At 4 weeks post-transplant the distribution of
normal and MPS VII iPSC-NSCs engrafted cells was similar to the distribution in non-MPS VII
NOD/SCID littermates, with cells found predominantly in the ventricles surrounding the
hippocampi (Fig. 3.2). Thus the disease state of the mice did not alter the engraftment properties
of donor cells. The iPSC-NSCs survived for at least four months (Fig. 3.3) with the donor cells
predominantly located in the white matter at that time point. Engrafted iPSC-NSCs remained in
an immature stage even after four months in vivo, as indicated by human-specific nestin
immunostaining (Fig. 3.3). Interestingly, the same cells injected into the striatum of neonatal
mice did reveal some evidence of differentiation to DCX-positive and β-III tubulin-positive
neuronal cells (Fig. 3.4). Despite their immature phenotype, transplanted iPSC-NSCs quickly
exited the cell cycle. At 1 week post-transplant, only a few cells expressed the cell proliferation
marker Ki67 and no Ki67-positive cells were seen at 4 or 16 weeks post-transplant (Fig. 3.5).
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Fig. 3.1 Distribution of Engrafted MPS VII iPSC-NSCs. 100,000 GFP-labeled iPSCNSCs were injected into the lateral ventricles of neonatal NOD/SCID mice. (a) Diagram of the
brain shows the relative rostral-caudal positions of the images below. (b) One month posttransplant, cells were found along the rostral-caudal axis of the brain, often adjacent to ventricles
and within white matter tracts. The areas within the white boxes are enlarged in the bottom
panels, showing the morphology of engrafted iPSC-NSCs. Scale bars = 500µm in upper panels
of (b) and scale bar = 200µm in lower panels of (b).

33

Figure 3.2 Host Genotype does not Affect Neonatal Engraftment.
(a,b) Representative sections from two NOD/SCID animals transplanted with GFP labelled MPS
VII iPSC-NSCs 4 weeks following neonatal transplantation. (c,d) Similar sections from 2
NOD/SCID/MPS VII animals. Regardless of host genotype, transplanted cells are predominantly
found in near ventricles, often surrounding the hippocampus. Scale bar = 200µm.
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Figure 3.3 MPS VII iPSC-NSCs survive and retain nestin expression four months following intraventricular injection.
The presence of engrafted iPSC-NSCs was revealed by immunostaining four months after neonatal transplantation. The highest
concentrations were found in and along white matter tracts. (a) Black boxes over Nissl stained coronal sections show the locations of
engrafted MPS VII iPSC-NSCs seen below. The location relative to bregma (in mm) is shown above each section. (b) Engrafted MPS VII
iPSC-NSCs remained nestin-positive even after four months in vivo. Scale bar = 200µm, cc = corpus callosum, vhc = ventral hippocampal
commissure, opt = optic chiasm. Nissl stained sections from the Allen Mouse Brain Atlas (Allen Institute for Brain Science).

Figure 3.4 Differentiation of MPS VII iPSC-derived NSCs in neonatal striatum.
When uncorrected GFP-labeled cells were injected into the stratum of NOD/SCID mice, we saw
very little migration after one month. However, there was some evidence of differentiation. DCXpositive neuronal precursors with leading processes could be seen migrating away from the
injection site (top row), while β-III tubulin-positive cells remained at the injection site (bottom
row). Mouse neurons are not seen in the background because the antibody binds much more
strongly to human β-III tubulin. This result shows that environmental signals play a role in
determining the differentiation status of engrafted cells within the neonatal mouse brain.
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Figure 3.5 MPS VII iPSC-NSCs Quickly Exit the Cell Cycle Following Neonatal
Transplantation. (a) MPS VII iPSC-NSCs in vitro prior to transplantation. The majority of cells
stain positive for Ki67, a marker of cell division. (b) Vibratome section of NOD/SCID brain, one
week following neonatal transplantation. Very few transplanted cells were co-labeled with both
human specific nuclei and Ki67. (c,d) No cells were found co-labeled with both human specific
nuclei and Ki67 4 weeks or 16 weeks post-transplantation, indicating that transplanted cells are
no longer dividing at these time points. Scale bars = 200µm.
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Therapeutic potential of corrected MPS VII iPSC-NSCs
MPS VII is a progressive disease with extensive pathology present by two months of age
(Snyder et al. 1995, Levy et al. 1996). Therefore, two-month-old NOD/SCID/MPS VII mice were
injected bilaterally into the striatum with 50,000 corrected MPS VII iPSC-NSCs in one hemisphere
and 50,000 mock-corrected cells in the contralateral hemisphere. Animals were sacrificed one
month later. Engrafted cells survived, remained nestin-positive, and did not migrate away from
the injection site. GUSB enzymatic activity, detected by a histochemical reaction (Snyder et al.
1995) was limited to the injection site of the hemisphere receiving corrected cells (Fig. 3.6).
To test whether the lack of differentiation and migration was unique to our MPS VII line or
to the diseased environment, we transplanted iPSC-NSCs derived from a healthy human control,
as well as MPS VII iPSC-NSCs, into NOD/SCID (non-MPS VII) adult mice. At 1 month posttransplant, engrafted cells from both lines remained at the injection site and stained positive for
human-specific nestin (Fig. 3.7). iPSC-NSCs from a normal and diseased source had the same
properties when transplanted into adult brain parenchyma, demonstrating that the MPS VII iPSCNSC line used in our studies was not unique in this respect.
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Figure 3.6 Corrected and Uncorrected MPS VII iPSC-NSCs Transplanted into Adult
MPS VII Mouse Brain. 50,000 cells were injected bilaterally into the striatum of two month old
NOD/SCID/MPS VII mice. One hemisphere received corrected MPS VII iPSC-NSCs and the
other hemisphere received mock-corrected MPS VII iPSC-NSCs. One month following
transplantation, enzyme activity was present at the injection tract in the hemisphere receiving
corrected cells, but not in the hemisphere receiving mock-corrected cells. n=4 mice, scale bar =
0.25mm.
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Figure 3.7 MPS VII and Control iPSC-NSCs Transplanted into Adult Mouse
Striatum. (top row) Human specific nestin staining of sections from adult NOD/SCID mice one
month post-transplantation with MPS VII iPSC-NSCs into adult striatum at two months of age (n =
7 mice). (bottom row) Human specific nestin staining of sections from adult NOD/SCID mice
one month post-transplantation with iPSC-NSCs derived from a normal control (n = 5 mice).
MPS VII and normal iPSC-NSCs remain at the injection site and stain positive for the NSC
marker nestin. Scale bar = 200µm.
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Immunofluorescent Analysis of MPS VII animals at 3 Months of Age
Given that MPS VII is a gradually progressive neurodegenerative disease, we evaluated
a number of antibodies in frozen 20µm thick NOD/SCID/MPS VII brain sections at 3 and 8
months of age to determine the best markers of pathology at 3 months, the age at which our
experimental animals were sacrificed (Fig. 3.8). We evaluated a number of markers known to be
pathologically upregulated late in the disease process, but it was unknown to what extent these
markers would be useful in 3 month old animals. We examined lysosomal distention (LAMP2),
astrogliosis (GFAP), secondary substrate accumulation (gangliosides GM2 and GM3), and a nonspecific fluorescent stain commonly used to mark degenerating neurons (Fluoro-Jade C)
(Schmued et al. 2000). We also evaluated the extent of microglial activation (via CD68
immunostaining) as extensive microglial pathology has been reported in some, but not all LSDs
(e.g. MPS IIIB, less so in MPS I) (Wada et al. 2000, Ohmi et al. 2003). Neuro-inflammation is a
common finding in MPS diseases (Archer et al. 2014), and microarray analysis of MPS VII brains
from our lab showed that CD68, a major marker of microglial activation (Kreutzberg 1996), is
transcribed at very high levels in the brain relative to normal mice (~10-fold higher across all brain
regions) (Parente et al. 2012). In fact, 25 of the top 36 genes upregulated relative to normal
brains were associated with the manually curated “immune/inflammation” theme using DAVID
functional annotation analysis (Huang da et al. 2009, Parente et al. 2012). We confirmed via
immunostaining that CD68 was highly upregulated in NOD/SCID/MPS VII animals early in the
disease process, preceding the appearance of other commonly used markers of neuropathology.
CD68-positive microglia were uniformly distributed throughout the MPS VII brain by three months
of age whereas CD68 was limited to small intracellular punctae within microglia of normal mice
(Fig. 3.8 and 3.11d).
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Figure 3.8 CD68-Positive Activated Microglia Precedes the Appearance of Other
Markers of Neurodegeneration. NOD/SCID and NOD/SCID/MPS VII mice brain sections
stained at three and eight months of age. (a,b) Markers of neuropathology in three month-old
mice and (c,d) eight month-old mice. Lysosomal distension (LAMP2), secondary substrate
accumulation (gangliosides GM2 and GM3), astrogliosis (GFAP), and neurodegeneration (Fluoro+

Jade C) occur after the appearance of CD68 microglia. LAMP2 = Lysosome-Associated
Membrane Glycoprotein 2, GFAP = Glial Fibrillary Acidic Protein GM2 = GM2 ganglioside, GM3 =
GM3 ganglioside. Scale bar = 200µm.
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Confirmation of CD68-Positive Microglia as a Marker of MPS VII Pathology
To confirm that CD68 staining is a reliable marker for MPS VII neuropathology in 3
month-old animals, we injected 2 month-old BL6/MPS VII mice bilaterally with an adenoassociated viral vector encoding GFP (AAV1-GFP) in one hemisphere and a 1:1 mixture of
AAV1-GFP and AAV1-GUSB in the other hemisphere (Fig. 3.9). The total dose of vector was
11

held constant at 1x10 . We confirmed via immunostaining that CD68-positive microglia were
already widespread by 2 months of age (data not shown). The mice were sacrificed at three
months and frozen sections were stained for enzyme activity and CD68. The spherical nature of
CD68-positive microglia combined with their relatively uniform distribution allowed us to develop a
straightforward method of schematizing CD68 in whole brain sections.
Using Photoshop to merge individual immunofluorescent images, combined with
ImagePro software to identify and dilate all objects with an area greater than 20 pixels, we
created schematics of CD68 that were easily amenable to quantification. Adjacent sections were
stained for enzyme activity using a sensitive colorimetric enzyme assay for the localization of βglucuronidase activity based on the cleavage of Naphthol AS-BI β-D-glucuronide and its
subsequent reaction with a pararosaniline dye to create an insoluble product that is easily
visualized (the HPR assay) (Wolfe et al. 1990, Gallagher 1992) (Fig. 3.9a). Co-immunostaining
of GFP and CD68 clearly shows a reduction in the number of CD68-positive cells surrounding the
region that received the mixture of AAV1-GFP and AAV1-GUSB but not in the region receiving
AAV1-GFP alone (Fig. 3.9b).
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Figure 3.9 Absence of CD68-Positive Microglia Correlates with β-glucuronidase
Activity in MPS VII animals. MPS VII mice were injected with a mixture of AAV1-GFP and
AAV1-GUSB in one hemisphere, while the contralateral hemisphere was injected with AAV2/111

GFP alone (total of 1x10 vector genomes, n=4 mice). (A) A schematic of a CD68
immunostained section shows a lack of CD68-positive microglia in the area surrounding the site
injected with AAV1-GUSB one month post-injection. (B) GFP and CD68 immunostaining shows
a reduction in activated microglia surrounding the injection site of AAV1-GUSB + AAV1-GFP but
not around the injection site of AAV1-GFP alone. Scale bar = 200µm.
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Evaluation of Pathology Following Neonatal Intraventricular Transplantation
To determine if corrected or mock-corrected MPS VII iPSC-NSCs affected
neuropathology in MPS VII mice, changes in activated microglia were used as a marker of
neuropathology. Three months following transplantation, engrafted cells could be found across
the brain, but at low densities, similar to those seen following primary NSC grafts (Fig. 3.1 and
3.3). The HPR assay reveled cells clustered primarily in periventricular regions between the
hippocampus and corpus callosum. CD68-positive microglia were not reduced even in the
regions directly adjacent to transplanted cells (Fig. 3.10).

Evaluation of Pathology Following Adult Striatal Transplantation
One month following adult transplantation, there was a striking reduction in CD68
immunoreactivity surrounding the corrected MPS VII iPSC-NSC grafts, but not the mockcorrected grafts (Fig. 3.11). The density of CD68-positive cells was quantified in a 0.5 mm

2

region of interest (ROI) surrounding each injection tract (Fig. 11c). There was a significant
2

difference between the region surrounding corrected grafts (49.2 ± 9.9 cells/mm ) and the region
2

surrounding mock-corrected grafts (145.2 ± 13.2 cells/mm , p<0.0001) (Fig. 3.11c). There was
not a significant difference between the region surrounding mock-corrected grafts and a
2

comparable region of untreated MPS VII striatum (166.1 ± 13.4 cells/mm , p>0.05).
Immunostaining for CD68 and the pan-microglial marker Iba1 showed that the microglia in
untreated MPS VII mice as well as the microglia surrounding mock-corrected iPSC-NSCs had a
distended, amoeboid-type morphology (Fig. 3.11d). The region surrounding corrected iPSCNSCs contained smaller, ramified-type microglia, which closely resembled the microglia in normal
control brains (Fig. 3.11d).
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Figure 3.10 Low Levels of Engraftment Following Neonatal Transplantation do not
Reduce CD68-positive Microglia
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Figure 3.10 Low Levels of Engraftment Following Neonatal Transplantation do not
Reduce CD68-positive Microglia. NOD/SCID/MPS VII neonates and their non-MPS VII
littermates were injected intraventricularly with 50,000 corrected MPS VII patient iPSC-derived
NSCs or PBS. The sensitivity of the HPR assay (left column) allowed for the detection of subtherapeutic levels of levels of β-glucuronidase activity in engrafted cells (red stained areas).
CD68-positive cells were widespread in mice receiving PBS or corrected iPSC-derived NSCs,
even in areas directly adjacent to corrected cells (right column). Normal littermates showed no
signs of CD68-positive microglia at this suddestin, Anlaysins of.

47

Figure 3.11 Correction of Microglial Pathology Following Adult iPSC-derived NSC
Transplantation.
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Figure 3.11 Correction of Microglial Pathology Following Adult iPSC-derived NSC
Transplantation. Corrected and mock-corrected iPSC-NSCs (50,000 cells/condition) were
injected intrastriatally into the right and left hemisphere respectively, of adult NOD/SCID/MPS VII
mice. (a) Schematic of a representative coronal section showing engrafted MPS VII iPSC-NSCs
and CD68-positive microglia one month post-transplantation. (b) Immunofluorescent images of
nestin-positive iPSC-NSCs at the site of injection. The region surrounding the corrected MPS VII
iPSC-NSCs contained significantly fewer activated microglia than in the region surrounding mockcorrected MPS VII iPSC-NSCs or in a comparable region of untreated MPS VII striatum. CD68positive microglia with an area greater than 20 pixels was quantified (c). (d) Confocal images of
Iba1 and CD68 immunoreactivity in resident microglia. The brains of MPS VII mice showed
marked microglial activation, as evident by upregulated CD68 expression and amoeboid
morphology. Microglia adjacent to corrected, but not mock-corrected, MPS VII iPSC-NSCs
exhibited a ramified morphology and low CD68 expression typical of the quiescent microglia
found in normal mice. Mean ± SEM, n=3 sections/mouse, n=4 mice, scale bar = 200µm in (b)
and 30µm in (d).
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III. Discussion
In Chapter 2 we showed that MPS VII patient-derived iPSCs can be differentiated into
long-term self-renewing NSCs, similar to iPSCs from an unaffected control. In order to evaluate
the engraftment potential of these cells we transplanted them within the ventricles and striatum of
neonatal NOD/SCID mice. We then tested the therapeutic potential of these cells by quantifying
microglial pathology surrounding corrected and mock-corrected grafts in MPS VII mice.
Cells transplanted intraventricularly into neonatal mice survived and engrafted throughout
white matter tracts in the brain. However, they remained nestin-positive even 4 months posttransplantation. In contrast, Koch et al. found mature engrafted neurons at the same time point
following neonatal telencephalic injections using similar ESC-derived NSCs (Koch et al. 2009).
We ruled out the possibility that reactivation of the retroviral transgenes was responsible for the
lack of differentiation by co-immunostaining using antibodies against human nuclei and Oct4. Our
experiments primarily utilized intraventricular injections to maximize the spread of engraftment,
and we hypothesized that the site of injection might explain the lack of differentiation. We found
that injecting cells into the striatum of neonatal mice resulted in some neuronal differentiation one
month post-transplantation. In contrast to the cells found in the white matter after intraventricular
injection, we found DCX-positive neuronal precursors and β-III tubulin-positive neurons with an
immature morphology near the injection site. The engrafted cells failed to migrate far from the
striatal injection site. This is consistent with previous studies showing that the location of
engraftment makes a difference in the differentiation and migration potential of transplanted
NSCs (Watson et al. 2006).
The mouse sub-ventricular zone (SVZ) provides a niche for stem cells in the mouse
brain, and this may serve to inhibit NSC differentiation (Ghashghaei et al. 2007). Autoattraction
of transplanted cells likely plays a role in the lack of migration. The same group that first
demonstrated the ESC to NSC protocol used in the Koch et al. study Iater published a report
demonstrating that NSCs transplanted onto live brain slices failed to migrate (Ladewig et al.
2014). They used cells expressing GFP under the control of the DCX promoter to distinguish
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between NSCs and neural progenitor cells (NPCs). After sorting DCX-positive cells they
transplanted a pure population of NPCs and found that they migrated very well. They
demonstrated that blockade of VEGF and FGF2 receptors on the surface of neural progenitor
cells (NPCs) allowed for greater migration in the presence of NSCs. This was accomplished
using antibodies against VEGF and FGF2 receptors or a tyrosine kinase inhibitor, nintedanib
(Ladewig et al. 2014). This is consistent with our results and the results of other studies showing
that chemoattractant signaling plays a large role in NSC migration. NSCs are known to migrate
towards areas of injury, such as tumors or even the needle track created during the surgical
procedure (Aboody et al. 2000, Boockvar et al. 2005). Chemokines such as PDGF and stromal
cell-derived factor 1α (SDF-1α, or CXCL12) are likely to play a role in attracting NSCs expressing
CXC chemokine receptor 4 (CXCR4) (Imitola et al. 2004, Ladewig et al. 2014).
One week following neonatal transplantation, cells were found primarily within and
adjacent to ventricles. After one month, cells were widely distributed throughout white matter
tracts. This is consistent with many studies showing that NSCs from various sources display a
tropism for white matter in both normal and pathological contexts (Tabar et al. 2005, Maciaczyk et
al. 2009, Carney et al. 2011, Gupta et al. 2012). This affinity for white-matter tracts may be useful
for treating leukodystrophies or as a pathway for NSC dissemination. The limited migration of
transplanted NSCs within grey matter may be a barrier to widespread delivery for some diseases
with global CNS pathology; however, axonal transport can facilitate wider distribution of
lysosomal proteins within this group of diseases (Passini et al. 2002).
Another factor limiting engraftment is donor cells exiting the cell-cycle. While iPSC-NSCs
grew prolifically in culture, they stopped dividing shortly after transplantation. Very few Ki67positive cells were found one week post-transplantation and no Ki67-positive cells were found at
one or four moths post-transplantation. Ideally, a population capable of limited or controlled cell
division will strike the delicate balance between total engraftment levels and the risk of
tumorigenesis.
Due to the intrinsic variation between ESC and iPSC lines, we were concerned that the
results we found following transplantation were specific to our MPS VII iPSC line. As a control,
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we transplanted an iPSC line derived by an independent source (the CHOP iPSC core) using a
different reprogramming method (Cre-excisable constitutive polycistronic lentivirus) (Sommer et
al. 2010). Based on the similar behavior of the lines, we concluded that the results were not an
artifact of our particular line.
A major hurdle we overcame was the evaluation of pathology in treated brains at 3
months-of-age. Neuropathology of MPS VII is often evaluated in very thin sections (0.5-5µm),
necessitating that brains be embedded in plastic (e.g. JB4), epoxy (e.g. Epon), or paraffin (Heuer
et al. 2002, Liu et al. 2005, Mikula et al. 2012). We opted to use thicker (~20µm) frozen sections
to evaluate pathology for several reasons: 1) The antibodies used in these studies were validated
and optimized using frozen sections 2) paraffin, plastic, or epoxy sectioning of so many brains
(>100) was impractical, and 3) The use of plastic or epoxy sections generally precludes IHC,
reducing our ability to co-localize engrafted cells and pathology (Shi et al. 1991, McCluggage et
al. 1995, Cai et al. 2005).
We systematically evaluated antibodies validated in older animals in addition to
antibodies against candidate proteins identified by microarray. We found that only CD68 was
highly upregulated in MPS VII animals at 3 months of age, and therefore decided to use this as
our primary readout of pathology.
Neonatally engrafted cells migrated widely, and could be visualized immunofluorescently
using antibodies against GFP, human nuclei, and human-specific nestin. They could also be
visualized using the highly sensitive HPR assay. Unfortunately, there was no difference in CD68positive microglia, even directly surrounding the transplanted cells. In contrast, our adult
transplantation experiments unambiguously show that a high local concentration of corrected
MPS VII iPSC-NSCs cleared CD68-positive microglia in an area surrounding the graft. Ramified
microglia in the corrected region had small soma and extended processes, consistent with a
quiescent microglial state (Kreutzberg 1996).
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CHAPTER 4
Conclusions and Future Directions
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Figure 4.1 Graphical Outline of an iPSC-derived NSC-based Strategy for βglucuronidase Replacement in the Brain using a Xenograft Model of MPS VII.
The general use of this strategy involves removing somatic cells from the patient, reprogramming
them via introduction of the transcription factors Oct4, Sox2, Kl4, and c-MYC. Using
differentiation protocols developed for ESCs/iPSCs, pluripotent cells can be converted to longterm self-renewing neural stem cells. Introduction of the GUSB gene via DNA transposonmediated (PiggyBac) gene delivery rescues the mutant phenotype in cells. Following
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transplantation in the brain, β-glucuronidase is secreted by corrected cells and taken up by
nearby affected cells, thereby reducing pathology in vivo.

I. Conclusions
Here we demonstrate the feasibility of ex vivo gene therapy for the treatment of
neuropathology accompanying metabolic disease using patient-derived somatic cells from a
readily accessible source (e.g. frozen skin biopsy). By reprogramming patient fibroblasts into
pluripotent stem cells and subsequently generating genetically corrected tissue-specific stem
cells, we evaluated a therapeutic strategy that can be applied to many genetic diseases affecting
the brain. We show, via xenotransplantation into a mouse homologue of the human disease, that
such a strategy can reverse pathologic lesions surrounding engrafted cells.
The success of NSC-based therapy will depend on protocols that yield well-characterized
and expandable lines suitable for transplantation. We chose an NSC differentiation protocol for its
ability to generate a self-renewing population of relatively homogenous NSCs from ESC and
iPSC lines (Koch et al. 2009, Falk et al. 2012). The in vitro characteristics of MPS VII iPSC-NSCs
generated here were consistent with reports utilizing similar ESC-based protocols in regards to
the immunophenotype and ability to generate predominately GABAergic neurons upon withdrawal
of growth factors (Koch et al. 2009).
We found that GUSB deficiency did not compromise the ability of human MPS VII iPSCs
to generate embryoid bodies or differentiate towards neural lineages, in contrast to a previous
report on mouse MPS VII iPSC lines (Meng et al. 2010). Disease-related phenotypes have been
reported, in vitro, in iPSCs derived from patients with other LSDs such as Niemann-Pick type C or
MPS IIIB (Lemonnier et al. 2011, Bergamin et al. 2013), and in primary canine MPS VII NSCs
(Walton et al. 2007). However, there was no evidence in our study that the MPS VII iPSC-NSCs
or their progeny had a disease-related phenotypic difference in vitro. We directly compared
corrected and mock corrected NSCs by immunofluorescent analyses and found no significant
differences. We also co-cultured corrected or mock-corrected iPSC-NSCs with primary cortical
cells derived from MPS VII or normal littermate controls (data not shown). After loading the co-
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cultures with a calcium dependent fluorescent dye, we were able to visualize several network
properties in real time (Patel et al. 2015). While these experiments were preliminary, we found no
differences in network firing properties between corrected iPSC-NSC/MPS VII cortical co-cultures
and mock-corrected iPSC-NSC/control cortical co-cultures. Furthermore, the GUSB deficiency did
not impair engraftment as we observed no apparent differences in the number or distribution of
genetically corrected and mock-corrected MPS VII iPSC-NSCs following transplantation into MPS
VII mice. More GUSB-negative cell lines are needed to determine if this phenomenon is specific
to our MPS VII line or merely reflects the subtlety of the disease.
Transplantation of iPSC-NSCs within the neonatal brain yielded stable engraftment
across the neuroaxis for at least four months, but only within and adjacent to white matter tracts.
Although the precise mechanisms are unclear, NSCs from various sources display a tropism for
white matter in both normal and pathological contexts (Tabar et al. 2005, Maciaczyk et al. 2009,
Carney et al. 2011, Gupta et al. 2012). The affinity for white-matter tracts may be useful for
treating leukodystrophies and as a pathway for NSC dissemination. The limited migration of
transplanted NSCs within grey matter precludes widespread delivery for some diseases with
global CNS pathology, however axonal transport can facilitate wider distribution of lysosomal
proteins within this group of diseases (Passini et al. 2002).
We transplanted iPSC-NSCs into neonatal mice in order to evaluate their behavior in a
more appropriate developmental context. Many of the cues required for survival and migration of
NSCs are present in neonates but not in healthy adults (Guzman et al. 2007). We found that
iPSC-NSCs engrafted widely but sparsely, which is consistent with neonatal transplants of
primary mouse NSCs (Chaubey et al. 2013). Following transplantation directly into grey matter
(adult striatum), the iPSC-NSCs remained localized to the injection tract. As a consequence,
microglial pathology was corrected in a zone surrounding the graft, corresponding to the
distribution of enzyme in three dimensions in the brain parenchyma (Taylor et al. 1997). In
contrast, neonatal transplants engrafted throughout the white matter but were too sparse to
significantly reduce the number of CD68-positive cells, even in regions directly adjacent to
corrected cells. Thus, substantial improvements to increase both the density and distribution of
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donor cells within the brain will be needed to deliver the therapeutic enzyme to more areas of the
brain to advance clinically relevant NSC therapy further for LSDs.
The engrafted iPSC-NSCs showed very little evidence of differentiation, even four
months post-transplant. The absence of mature neurons and glia following neonatal and adult
transplantation stands in contrast to the efficient differentiation of iPSC-NSCs in vitro. This result
underscores the need for a better understanding of the environmental signals governing NSC
differentiation. However, for use in correcting most LSDs the differentiation status of engrafted
cells is not critical, provided that they do not cause deleterious effects in the brain.
Undifferentiated cells may in fact be advantageous, as inappropriate neurotransmitter release
from mature engrafted neurons can be harmful in some settings. One example of this is the graftinduced dyskinesias resulting from cell replacement therapy in Parkinson’s disease patients
(Lane et al. 2010).
Gene and cell based therapies that successfully deliver lysosomal enzymes in the brain
reduce pathology in many animal models of LSD (Simonato et al. 2013). To test whether
genetically corrected patient iPSC-NSCs could deliver corrective levels of GUSB, we evaluated
pathology in the adult striatum surrounding the graft. We assayed disease-associated
neuroinflammation as a biomarker, using CD68-positive activated microglia. Evidence for a
microglial contribution to MPS VII pathology was previously shown via microarray analysis of
normal and diseased brains (Parente et al. 2012). Microglial involvement has been well
documented in some, but not all, storage diseases including MPS IIIB and Sandhoff disease
(Wada et al. 2000, Ohmi et al. 2003), and activated CD68-positive microglia have been used as a
biomarker for correction of pathology (Lee et al. 2007). We show here that microglial activation is
a significant and early component of MPS VII neuropathology. CD68-positive microglia are
particularly useful as a quantifiable biomarker of MPS VII neuropathology because of their
distended size, spherical morphology, and uniform distribution.
We observed no differences in the engraftment capacity of corrected and mock-corrected
MPS VII iPSC-NSCs. Activated microglia adjacent to mock-corrected grafts appeared distended
and amoeboid, indistinguishable from microglia in comparable regions of the untreated MPS VII

57

brain. In contrast, the area surrounding corrected grafts contained significantly fewer CD68positive cells. The microglia were reduced in size and adopted a more ramified-type morphology
consistent with the phenotype of resting microglia seen in normal animals.
Mock-corrected grafts did not provide any therapeutic benefit, suggesting that GUSB
alone was responsible for correcting neuropathology, rather than anti-inflammatory or other
factors expressed by the iPSC-NSCs themselves. The observation that GUSB over-expression
from an AAV vector similarly reduces CD68-positive microglia corroborates the conclusion that
GUSB activity is solely responsible for the correction of neuropathology.
The spatially restricted nature of correction following cell transplantation indicates the
need for new differentiation protocols or other strategies capable of increasing NSC migration
within the brain parenchyma. Overall, our results suggest that a comprehensive strategy
involving somatic reprogramming and gene therapy could benefit patients with neuropathology
from storage diseases affecting the brain.

II. Issues Related to Measuring Neuropathology in MPS VII mice.
The amount of storage present in 3 month-old MPS VII animals proved insufficient to
reliably distinguish from controls. The presence of storage lesions at this time point has been
established via electron microscopy (Levy et al. 1996) and immunostaining of poly-ubiquitin
inclusions in paraffin sections (Heuer et al. 2002). However, the limited distribution of our grafts
combined with the small percentage of NOD/SCID/MPS VII offspring from heterozygous breeding
pairs made these strategies impractical on a scale needed to adequately power our studies. Our
original plan was to stain frozen cryosections with antibodies that had been validated on 8 monthold animals. However, there was very little difference between 3 month-old normal and mutant
mice using these antibodies, including the same poly-ubiquitin antibody used previously on
paraffin embedded sections of 3 month-old mice. Standard immunoflourescent detection of
pathology becomes problematic as autofluorescent material accumulates over time in mutant
animals. By 8 months-of age there is extensive autofluorescent material accumulated throughout
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the brain, preventing all but the best antibodies from discriminating between real signal and
autofluorescence. Of all the antibodies we tested using cryosections of 3 month-old
NOD/SCID/MPS VII brains, α-CD68 clearly stood out. The pan-microglial markers Iba1 and
CD11b confirmed that microglial activation precedes other hallmarks of pathology. The spherical,
uniformly distributed nature of activated microglia in the MPS VII brain made it possible to
develop an automated method of identifying and quantifying these cells in the areas surrounding
the iPSC-NSC grafts. Given that activated microglia are known to be present at an early age in
many lysosomal storage diseases, we hope that this simple method of software-based
quantitative fluorescent image analysis may prove useful for the field. Importantly, this activation
is not strain-specific, and is readily detectible in both NOD/SCID/MPSVII and BL6/MPS VII by 2
months of age, the earliest time point examined.

III. Future Aims
By genetically correcting MPS VII iPSCs at the NSC stage we limited ourselves to using
only these cells for all transplantation experiments. Genetically manipulating cells at the iPSC
stage would allow us to test multiple differentiation protocols. To this end, we modified the iPSC
culture conditions allowing us to transfect cells and select stably transfected iPSCs with improved
versions of our PiggyBac vectors that contain the GUSB promoter (Fig. 4.2). Another concern is
line-to-line variability among individual ESC and iPSC lines. Given that there is always some
level of variability in terms of gene expression and differentiation potential, it is desirable to
generate more MPS VII lines. Given the rarity of the disease, and the fact that we had to derive
our MPS VII iPSC line from frozen fibroblast samples (a very inefficient process), it may not be
worth the time and effort to derive more lines directly from patient samples.
The use of recently developed gene editing technologies (e.g. TALEN and CRISPR) may
be a more attractive option for generating GUSB-deficient pluripotent cell lines (Christian et al.
2010, Ran et al. 2013). Knocking out GUSB in well-established ESC lines such as H9 (Amit et al.
2000) or iPSC lines provides several advantages. Most MPS VII patients have some small but
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residual expression of β-glucuronidase, and eliminating all enzymatic activity may yield additional
insights into the function of the enzyme and the pathophysiology of disease. Another advantage
to using well established lines is that we can mitigate the effect of line-to-line variability inherent to
pluripotent stem cell lines. Our current plan is to knock out GUSB in the normal iPSC line used in
these studies as well as in the well-studied H9 ESC line. CRISPR guide RNAs have been
created and transfected into a normal iPSC line, and clones are currently undergoing genotyping
and enzymatic analysis to confirm that no β-glucuronidase is present. Multiple GUSB ESC and
-/-

+/+

iPSCs lines compared to their parental GUSB

lines would provide further evidence that patient-

specific iPSC-NSCs (or other progenitor cell types) can be a safe and effective therapy for LSDs
in the brain.
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Figure 4.2 Genetically Corrected and Mock-Corrected MPS VII Patient iPSC labeled
with GFP. MPS VII iPSCs were dissociated into single cells and transfected with one of two
optimized PiggyBac transposon vectors described previously (Fig. 2.5). The use of the GUSB
promoter (rather than CMV or CAG) resulted in much higher β-glucuronidase levels in 293t cells
while maintaining GFP expression from the downstream EF1α promoter. Transfecting and
plating iPSCs on a high concentration of Matrigel in the presence of the ROCK inhibitor Y-27632
resulted in many colonies surviving, a small percentage of which were GFP positive. Several
clones from each condition were isolated and expanded. Correction of patient iPSCs allows for
the evaluation of multiple differentiation methods to increase survival and migration following
transplantation.
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IV. Future CNS Cell Therapy
The studies undertaken here, combined with results from many other groups,
demonstrate that the exact method of deriving NSCs, the source, the age of transplantation, the
transplantation site, and the pathological state of the host brain can dramatically alter the fate of
transplanted NSCs (Snyder et al. 1992, Snyder et al. 1995, Taylor et al. 1997, Boockvar et al.
2005, Tabar et al. 2005, Corti et al. 2008, Koch et al. 2009, Maciaczyk et al. 2009, Chaubey et al.
2013, Jensen et al. 2013, Mazzini et al. 2015). Our data suggest that early-stage NSCs may not
be ideal for widespread cell therapy in the brain. Several promising pluripotent stem cell-derived
alternatives have been recently developed that deserve to be more thoroughly evaluated in a
therapeutic context.
One approach involves the migratory progeny of long-term self-renewing NSCs similar to
the iPSC-NSCs used in our experiments. After initiating the differentiation process, Laedewing et
al. showed that DCX-positive neuroblasts, derived from non-migratory NSCs, migrated
extensively in slice culture (Ladewig et al. 2014). Another ESC-derived cell type shown to
migrate widely in the brain has been generated by mimicking the developmental cues
encountered by cells in the medial ganglionic eminence (MGE). The MGE is a subcortical
structure adjacent to the embryonic lateral ventricles. It is the birthplace of most cortical
interneurons, which must migrate long distances before functionally integrating into cortical
circuits (Wonders et al. 2006). Highly migratory MGE-like cells derived from human ESC/iPSCs
can be selected based on their expression of the transcription factor NKX2.1 (Maroof et al. 2013).
A drawback of these approaches is the requirement of fluorescent reporters to purify the cell-type
of interest from a heterogeneous population. Refinements to differentiation protocols or the
identification of cell surface markers will be required before these cell types can be used clinically.
Currently, one of the most promising approaches to achieving widespread CNS
engraftment involves glial progenitor cells (GPCs) rather than NSCs. GPCs, also known as
+

oligodendrocyte precursor cells or NG2 glia, comprise the majority of mitotic cells in the adult
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human brain and as much as 5-10% of total cells, depending on the region (Dimou et al. 2015).
In adults, GPCs are primarily responsible for generating oligodendrocytes for the purpose of
mylenating axons, but are capable of differentiating into astrocytes and even neurons (Rivers et
al. 2008, Sim et al. 2009). GPCs can be purified from primary human tissue using surface
markers including NG2, A2B5, and PDGFRA (Goldman et al. 2012). They can also be generated
in vitro from ESC/iPSCs or via direct reprogramming (Wang et al. 2013, Yang et al. 2013).
Human GPCs, whether derived from primary tissue or pluripotent cells, have the rather
amazing quality of actively displacing murine glia following adult transplantation (Windrem et al.
2014). Over the course of a year, transplanted human GPCs migrated throughout the white
matter and gradually advanced into the cortex, eliminating endogenous glia and supplanting their
function. Furthermore, engrafted mice demonstrated increased synaptic plasticity and performed
better on several cognitive tasks. Relative to mice engrafted with murine GPCs and unengrafted
mice, animals engrafted with human cells showed enhanced long-term potentiation (LTP), maze
performance, fear conditioning, and object-location memory (Han et al. 2013). Engrafted glia
were morphologically and functionally human, and unknown species-specific factors conferred a
clear competitive advantage. When the mechanism/s responsible are elucidated, it may be
possible to alter GPCs in vitro, giving the cells a similar advantage in an autologous host.
Microglia are major effectors of catabolism in the brain, and their correction or
replacement could restore a critical scavenger function in storage disease patients. With the
hope that bone marrow-derived stem cells would replace microglia and other macrophages while
providing a plentiful source of enzyme for the body, bone marrow transplantation (BMT) has been
performed on ~1000 LSD patients with generally disappointing results (Rovelli 2008). With the
exception of very young pre-symptomatic patients, BMT is usually not worth the significant risks.
Relative to other LSDs, BMT has been most successful in treating MPS I, and trials have shown
modest results for treating Krabbe disease and metachromatic leukodystrophy (Escolar et al.
2005, Biffi et al. 2013, Aldenhoven et al. 2015). A more thorough understanding of the factors
governing success and failure will facilitate the development of more effective cell therapies
targeting the brain.
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One important variable is the enzyme’s effective therapeutic dose. In the case of MPS
I, just 0.4% of normal catalytic activity can be enough to confer a relatively mild phenotype,
partially explaining the efficacy of BMT for this disease (Bunge et al. 1998). It’s important to
maximize the amount of enzyme produced by each engrafted cell. Take for example the recent
ex vivo gene therapy trial for metachromatic leukodystrophy (MLD) (Biffi et al. 2013). Lentiviral
overexpression of arylsulfatase A in conjunction with autologous BMT was very effective in
preventing disease, at least in a small group of pre-symptomatic patients.
Microglia and other tissue resident macrophages can self-renew, and they are not
normally replaced by cells from the bone marrow. In order to get significant numbers of bone
marrow-derived cells into the brain a niche must first be created. After killing resident myeloid
precursors in the brain with radiation or chemotherapy, bone marrow-derived cells entered the
brain and differentiated into microglia (Capotondo et al. 2012). This effect was seen with
busulfan, which crosses the blood-brain-barrier, but not with theosulfan, which does not
(Capotondo et al. 2012). Clinical trials that reported enzyme activity in the brain almost all used
busulfan as the primary chemotherapeutic (Rovelli 2008). PLX3397 is an inhibitor of the CSF-1
receptor (CSF1R) and it has the remarkable ability to kill all resident microglia over the course of
a few weeks. This compound was recently used to show that long-term microglial depletion in
adults has very little effect on behavior and that the microglial repopulating cells are likely
perivascular cells that transiently express nestin (Elmore et al. 2014). PLX3397 or similar drugs
may be important for creating a niche in which blood-borne donor cells have a real competitive
advantage in the brain.
The exact source of cells greatly influences the outcome as well. Umbilical cord stem
cells actually engrafted better than peripheral blood stem cells and bone marrow-derived stem
cells for MPS I (Boelens et al. 2007). iPSC-derived microglial precursors may be an ideal source
of enzyme in the brain capable of being delivered IV. Under the right conditions, it’s plausible that
myeloid progenitors could even replace resident macrophages throughout the body. A microglial
differentiation protocol has already been established for murine pluripotent stem cells, and should
be relatively straightforward to adapt it for human cells (Beutner et al. 2010). The success of cell
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transplantation for LSDs will depend on advances in differentiation techniques and transplantation
biology, which in turn rely on a broad understanding of the origins and behavior of cells in both
normal and pathological circumstances.
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Materials and Methods
Generation of MPS VII iPSCs
Frozen fibroblasts were obtained from a 3 month old female patient (GM02784, Coriell Institute
for Medical Research) with no detectable β-glucuronidase activity. Fibroblasts were maintained
in DMEM containing 15% FBS. Reprogramming was performed as previously described with
some modifications (Park et al. 2008). Retroviral vectors expressing Oct4, Sox2, Klf4, and c-Myc
were produced in 293t cells using the pMXs backbone (courtesy of Dr. Shinya Yamanaka,
Addgene plasmids 13366, 13367, 13375, and 17219) and pseudotyped with VSV-G (Takahashi
et al. 2006). MPS VII fibroblasts were transduced with the reprogramming vectors and after five
days were split onto mitomycin-C inactivated mouse embryonic fibroblasts (MEFs). The cells
were maintained in iPSC media containing ROCK inhibitor Y-27632 (10µM, Sigma) until colonies
were ready to be picked. Putative iPSC colonies were manually picked and transferred to fresh
MEFs. Subsequently, iPSC cultures were passaged either manually or enzymatically with
dispase (Gibco). Control iPSCs were obtained from the ESC/iPSC core of the Children’s Hospital
of Philadelphia, and generated using the Cre-excisable STEMCAA lentiviral vector (Sommer et al.
2010).
Teratoma formation
6

MPS VII iPSCs (1x10 ) were resuspended in 140µL DMEM/F12 and mixed with 60µL Matrigel
(BD biosciences). The cell suspension was injected subcutaneously in NOD/SCID mice (Jackson
Labs). Teratomas were removed 6 weeks later and either frozen for immunostaining or
embedded in paraffin for H&E staining.
Differentiation and culture of NSCs
MPS VII and control iPSCs were differentiated based on a protocol for generating long-term selfrenewing NSCs from ESCs (Koch et al. 2009). Briefly, iPSC colonies were removed from the
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MEF feeder layer and 20% FBS was added in order to generate embryoid bodies. At day five the
embryoid bodies were attached to poly-ornithine (Sigma) coated dishes and switched to a
minimal neural induction media containing insulin, transferrin, selenium, and fibronectin (Sigma)
until neural tube-like structures appear. At day 20 these tube-like structures were manually
removed from the surrounding cell mass using a dissecting microscope and transferred to a
suspension culture containing N-2 supplement (1:100, Gibco), bFGF (10 ng/mL, Gibco), and EGF
(10 ng/mL, Sigma). Cells were trypsinized at day 23 and plated on poly-ornithine/laminin (BD
biosciences) coated plates in NSC media containing bFGF (10ng\mL), EGF (10ng\mL), insulin
(20µg/mL, Gibco), N-2 (1:100), and B-27 (1:1000, Gibco). iPSC-NSCs were passaged 1:2 every
three to four days by trypsinization.
Characterization of iPSC-NSCs
G-banded karyotyping of iPSC-NSCs (p9) was performed by Cell Line Genetics. Terminal in vitro
differentiation was carried out in Neurobasal:DMEM/F12 (Gibco) containing N-2 (1:100), B-27
(1:100), and cyclic AMP (300ng/mL, Sigma) for one month. Quantification of the percentage of
undifferentiated and terminally differentiated iPSC-NSCs expressing cell-type specific markers
was performed by manual counting of immunofluorescently labeled slides. Percentages are
represented as means ± S.E.M. (n=4).
Gene transfer in MPS VII iPSC-NSCs
GFP labeling of iPSC-NSCs was achieved using a PiggyBac expression vector containing a
puromycin resistance gene (PB-513B-1, Systems Biosciences). The CMV promoter sequence
was replaced with the CAG promoter sequence using SpeI and EcoRI. GUSB was cloned into
the PiggyBac plasmid using SmaI sites flanking the GUSB cDNA and a SwaI site within the
multiple cloning site of the PiggyBac plasmid. Blunt-end ligation produced a correction vector as
well a mock-correction vector containing GUSB in the reverse orientation. For transfection of
iPSC-NSCs, we used the Lonza Kit for Mouse Neural Stem Cells according to the manufacturer
6

instructions. 4x10 cells were electroporated with 3µg of the GUSB expression vector or GFP
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control + 1µg of the transposase expression plasmid (PB200PA-1, Systems Biosciences) using
the Lonza Nucleofector set to program A-33. After allowing the cells a few days to recover,
transfected cells were selected with 0.5µg/mL puromycin for one week.
Neonatal NSC Transplantation
Neonatal NOD/SCID mice were cryoanesthetized prior to transplantation. iPSC-NSCs were
trypsinized and resuspended in PBS at 50,000 cells/µL. 2µL of the cell suspension was injected
into each lateral ventricle using a pulled glass micropipette. All procedures were approved by the
Institutional Care and Use Committee at the Children's Hospital of Philadelphia.
Adult NSC Transplantation
Prior to injection, 8 week old NOD/SCID or NOD/SCID/MPS VII mice (breeding stock was a kind
gift of Drs. M. Sands and J. Nolta) were anesthetized with isofluorane and secured in a sterotaxic
frame (Kopf). Burr holes were drilled into the skull and 50,000 corrected or mock-corrected cells
in 1µL PBS were infused at a rate of 0.5µl/minute. The striatal coordinates were: 0.50mm caudal
to bregma, 1.5mm left or right of midline, and 3.0mm ventral to the dural surface.
Adult AAV Injection
Prior to injection, 8 week old C57BL/6/MPS VII mice (n=4) were anesthetized with isofluorane
and secured in a sterotaxic frame (Kopf). Burr holes were drilled into the skull and AAV2/1 vector
in 1µL of PBS was infused at a rate of 0.5µl/minute. One hemisphere was injected with AAV2/1GFP, and the contralateral hemisphere was injected with a 1:1 mixture of AAV2/1-GFP and
11

AAV2/1-GUSB (total of 1X10 vector genomes). Packaging, purification, and tittering were
performed by The University of Pennsylvania Vector Core as previously described (Passini et al.
2003) The coordinates used for injection were: 0.50mm rostral to bregma, 1.5mm left or right of
midline, and 3.0mm ventral to the dural surface.
Immunostaining
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Brains were embedded in 2% agarose prior to vibratome sectioning and immunostaining. 60µm
coronal sections were stored in PBS + 0.1% Na azide at 4º until ready for use.

Brains were

cryoprotected with 30% sucrose prior to embedding in OCT (Tissue-Tek). 20µm-thick frozen
sections were cut using a cryostat (Leica). Vibratome and frozen sections were post-fixed in 4%
paraformaldehyde and permeabilized in 0.3% Triton X-100. After blocking in 4% goat serum, the
sections were incubated in primary antibody containing 1% serum for 1 hour at RT. Antibodies
used and their concentrations are listed in Supplemental Table 1. Images were acquired using
an epifluorescence microscope (DM6000 B, Leica) or a confocal-scanning laser microscope
(FluoView1000, Olympus).
Image analysis and statistics
To visualize the distribution of CD68-positive microglia in MPS VII mice following adult iPSC-NSC
engraftment, a montage of immunofluorescent images was combined using the photomerge tool
in Photoshop CS6 (Adobe). ImagePro Plus 3.0 (Media Cybernetics) was used to identify and
dilate all objects with an area greater than 20 pixels. CD68-positive microglia were quantified
within 0.25mm of engrafted iPSC-NSCs. The density of microglia adjacent to corrected and
mock-corrected cells was compared by two-tailed t-test using Prism 5.0 (Graphpad). Microglia
with a CD68-positive area greater than 20 pixels were counted. Frozen sections (20µm) were
quantitated for each condition, and data are represented as means ± S.E.M. (n=7).
β-glucuronidase assays
Napthol-AS-BI-β-D-glucuronide was used to determine the presence of GUSB activity in 20µm
thick frozen sections as previously described (Snyder et al. 1995). For quantitation of βglucuronidase activity in MPS VII and control NSCs, the fluorescence of hydrolyzed 4methylumbelliferyl-β-D-glucuronide was measured as previously described (Cervera 2005).
Three independent cultures were quantified, and data are represented as means ± S.E.M.
Gene transfer in iPSCs
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MPS VII and normal iPSCs, normally passaged using dispase, were dissociated into single cells
using TrpLE in the presence of 10µm Y-27632. The cells were plated on mitomycin-C inactivated
MEFs which were in turn plated on a 1:3 dilution of Matrigel. X-tremeGENE 9 (Roche) was used
to introduce PiggyBac (GUSB or revGUSB) and transposase plasmids 24 hr after iPSCs had
been plated. After one week, green colonies were picked and expanded.
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Figure 5.1 List of Antibodies used the Study

Antibody

Vendor

Catalog number

Concentration

mouse anti-SSEA4
mouse anti-Tra-1-60
mouse anti-Tra-1-81
mouse anti-human specific nestin
mouse anti-human specific nuclei
goat anti-DCX
mouse anti-β-III tubulin
mouse anti-MAP2
rabbit anti-GABA
rabbit anti-GFAP
mouse anti-Tyrosine hydroxylase
rabbit anti-KI67
rabbit anti-S100β
mouse anti-Oct4
mouse anti-c-Myc
mouse anti-O4
rabbit anti-Iba1
rat anti-CD68
rabbit anti-α-Fetoprotein
mouse anti-Smooth muscle actin
goat anti-mouse Alexafluor 488 or 594
goat anti-rat Alexafluor 594
donkey anti-goat Alexafluor 594
goat anti-rabbit Alexafluor 488 or 594

Millipore
Millipore
Millipore
Millipore
Millipore
Santa Cruz
Neuromics
Sigma
Sigma
Millipore
Sigma
Leica
Immunostar
Abcam
Sigma
Millipore
Wako
Abd Serotech
Abcam
Santa Cruz
Life Technologies
Life Technologies
Life Technologies
Life Technologies

MAB4304
MAB4360
MAB4381
MAB5326
MAB1281
sc8066
MO15013
M4403
A2052
AB5804
T1299
NCL-ki67p
22520
Ab18976
C3956
MAB345
019-19741
MCA1957
ab9372
sc-53142
A-11001/A11005
A-11007
A-11058
A-11008/A-11012

1:100
1:100
1:100
1:250
1:200
1:100
1:1000
1:500
1:1000
1:1000
1:1000
1:200
no dilution
1:100
1:500
1:100
1:1000
1:200
1:100
1:200
1:250
1:250
1:250
1:250
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